AngioDynamics, Inc. (ANGO)
Latham, NY, US
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| RITA | RITA | 2006-12-08 | View |
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.63% | -3.85% | +4.94% | +0.35% | -7.42% | -10.59% | +12.55% | +22.00% | -51.13% | -4.41% | -8.16% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 2 |
17.50
+20.6%
|
| All Time | 7 |
17.43
+20.1%
|
-
Revenue growth Medical - Instruments & Supplies: +7.9%-3.8% Q2'26: +8.0% (vs Q2'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+81.9% ★ Q2'26: -86.7% (vs Q2'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-5.7% Q2'26: +19.7% (vs Q2'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%-8.2% Q2'26: -12.6% (vs Q2'25)
-
ROIC Medical - Instruments & Supplies: +6.0%-18.9% Q2'26: -37.4% (vs Q2'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+2.0% Q2'26: +1.3% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.00× ★ Q2'26: 0.00× (vs Q2'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
May 2006 actual |
May 2007 actual |
May 2008 actual |
May 2009 actual |
May 2010 actual |
May 2011 actual |
May 2012 actual |
May 2013 actual |
May 2014 actual |
May 2015 actual |
May 2016 actual |
May 2017 actual |
May 2018 actual |
May 2019 actual |
May 2020 actual |
May 2021 actual |
May 2022 actual |
May 2023 actual |
May 2024 actual |
May 2025 actual |
May 2026 3 Rev. Ana. 2 EPS Ana. |
May 2027 3 Rev. Ana. 2 EPS Ana. |
May 2028 3 Rev. Ana. 3 EPS Ana. |
May 2029 2 Rev. Ana. 2 EPS Ana. |
May 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
78.45M
est: 60.28M (+30.1%)
|
112.23M
est: 82.63M (+35.8%)
|
166.50M
est: 155.53M (+7.1%)
|
195.05M
est: 175.34M (+11.2%)
|
216.04M
est: 182.61M (+18.3%)
|
215.96M
est: 194.64M (+11.0%)
|
221.79M
est: 202.89M (+9.3%)
|
342.03M
est: 246.41M (+38.8%)
|
354.46M
est: 294.22M (+20.5%)
|
356.97M
est: 357.75M (-0.2%)
|
353.69M
est: 348.98M (+1.3%)
|
349.64M
est: 353.46M (-1.1%)
|
344.29M
est: 345.29M (-0.3%)
|
359.48M
est: 355.48M (+1.1%)
|
264.16M
est: 268.37M (-1.6%)
|
291.01M
est: 286.73M (+1.5%)
|
316.22M
est: 312.13M (+1.3%)
|
338.75M
est: 338.40M (+0.1%)
|
303.91M
est: 292.73M (+3.8%)
|
292.50M
est: 286.65M (+2.0%)
|
314.12M
314.10M – 314.14M
+9.6% YoY
|
329.59M
324.63M – 334.54M
+4.9% YoY
|
348.47M
348.47M – 348.47M
+5.7% YoY
|
367.93M
363.93M – 371.46M
+5.6% YoY
|
391.64M
387.38M – 395.40M
+6.4% YoY
|
| EBITDA |
11.39M
est: 8.96M (+27.0%)
|
-7.82M
est: 13.53M (-157.8%)
|
25.11M
est: -3.01M (+934.3%)
|
27.94M
est: 26.75M (+4.4%)
|
32.82M
est: 24.88M (+31.9%)
|
23.78M
est: 27.88M (-14.7%)
|
10.19M
est: 18.92M (-46.1%)
|
34.76M
est: 15.06M (+130.8%)
|
37.32M
est: 21.32M (+75.0%)
|
24.92M
est: 38.20M (-34.8%)
|
28.25M
est: 20.08M (+40.7%)
|
13.36M
est: 36.07M (-63.0%)
|
8.96M
est: 19.12M (-53.1%)
|
16.28M
est: 34.56M (-52.9%)
|
-143.42M
est: 7.74M (-1,954.1%)
|
-9.28M
est: -142.82M (+93.5%)
|
11.13M
est: 1.57M (+610.6%)
|
12.19M
est: 10.18M (+19.8%)
|
-6.13M
est: 4.47M (-237.2%)
|
1.74M
est: 4.38M (-60.3%)
|
4.80M
4.80M – 4.80M
+9.6% YoY
|
5.03M
4.96M – 5.11M
+4.9% YoY
|
5.32M
5.32M – 5.32M
+5.7% YoY
|
5.62M
5.56M – 5.67M
+5.6% YoY
|
5.98M
5.91M – 6.04M
+6.4% YoY
|
| EBIT |
10.31M
est: 7.84M (+31.5%)
|
-11.23M
est: 10.15M (-210.6%)
|
16.24M
est: -12.76M (+227.2%)
|
15.88M
est: 16.60M (-4.3%)
|
20.29M
est: 14.23M (+42.6%)
|
11.20M
est: 18.06M (-38.0%)
|
-4.91M
est: 8.31M (-159.2%)
|
3.68M
est: -2.58M (+242.9%)
|
8.84M
est: 3.71M (+138.5%)
|
-4.94M
est: 17.59M (-128.1%)
|
132.0K
est: -8.96M (+101.5%)
|
-11.46M
est: 14.34M (-179.9%)
|
-14.20M
est: -4.14M (-243.0%)
|
-9.60M
est: 12.13M (-179.2%)
|
-167.23M
est: -18.29M (-814.3%)
|
-35.19M
est: -191.12M (+81.6%)
|
-18.22M
est: -26.67M (+31.7%)
|
-18.68M
est: -53.23M (+64.9%)
|
-33.84M
est: -20.83M (-62.5%)
|
-24.06M
est: -20.40M (-18.0%)
|
-22.35M
-22.35M – -22.35M
-9.6% YoY
|
-23.45M
-23.81M – -23.10M
-4.9% YoY
|
-24.80M
-24.80M – -24.80M
-5.7% YoY
|
-26.18M
-26.43M – -25.90M
-5.6% YoY
|
-27.87M
-28.14M – -27.57M
-6.4% YoY
|
| Net Income |
6.87M
est: 4.99M (+37.6%)
|
-9.13M
est: 7.62M (-219.8%)
|
10.89M
est: -12.10M (+190.0%)
|
9.93M
est: 10.47M (-5.1%)
|
12.31M
est: 8.72M (+41.2%)
|
8.12M
est: 10.57M (-23.2%)
|
-5.18M
est: 5.59M (-192.7%)
|
-1.21M
est: -5.90M (+79.5%)
|
2.35M
est: -1.56M (+250.7%)
|
-3.39M
est: 5.50M (-161.6%)
|
-43.59M
est: -7.26M (-500.4%)
|
-7.05M
est: -22.38M (+68.5%)
|
16.34M
est: -8.17M (+300.0%)
|
61.34M
est: 13.31M (+360.8%)
|
-166.79M
est: -17.37M (-860.2%)
|
-31.55M
est: -187.44M (+83.2%)
|
-26.55M
est: -204.9K (-12,854.8%)
|
-52.44M
est: 6.45M (-913.6%)
|
-184.35M
est: -246.44M (+25.2%)
|
-33.99M
est: -11.20M (-203.5%)
|
-6.63M
-6.71M – -6.54M
+40.9% YoY
|
-6.41M
-6.50M – -6.33M
+3.2% YoY
|
-1.28M
-1.91M – -650.9K
+80.0% YoY
|
7.79M
2.60M – 12.98M
+708.3% YoY
|
11.89M
11.72M – 12.03M
+52.6% YoY
|
| SGA |
29.35M
est: 21.32M (+37.6%)
|
56.84M
est: 31.71M (+79.2%)
|
61.47M
est: 74.22M (-17.2%)
|
76.92M
est: 65.10M (+18.2%)
|
77.36M
est: 67.88M (+14.0%)
|
75.95M
est: 67.23M (+13.0%)
|
82.84M
est: 70.92M (+16.8%)
|
102.25M
est: 79.79M (+28.1%)
|
109.24M
est: 82.00M (+33.2%)
|
110.49M
est: 102.24M (+8.1%)
|
114.12M
est: 117.36M (-2.8%)
|
110.23M
est: 91.34M (+20.7%)
|
108.54M
est: 103.63M (+4.7%)
|
116.13M
est: 107.05M (+8.5%)
|
116.51M
est: 120.76M (-3.5%)
|
117.22M
est: 211.97M (-44.7%)
|
133.75M
est: 138.70M (-3.6%)
|
144.25M
est: 283.80M (-49.2%)
|
143.98M
est: 130.08M (+10.7%)
|
145.23M
est: 127.38M (+14.0%)
|
139.59M
139.58M – 139.60M
+9.6% YoY
|
146.46M
144.26M – 148.66M
+4.9% YoY
|
154.85M
154.85M – 154.85M
+5.7% YoY
|
163.50M
161.72M – 165.07M
+5.6% YoY
|
174.04M
172.14M – 175.71M
+6.4% YoY
|
| EPS |
0.55
est: 0.35 (+57.1%)
|
-0.49
est: 0.54 (-190.7%)
|
0.45
est: 0.55 (-18.2%)
|
0.41
est: 0.48 (-14.6%)
|
0.50
est: 0.39 (+28.2%)
|
0.33
est: 0.39 (-15.4%)
|
-0.20
est: 0.37 (-154.1%)
|
-0.02
est: 0.30 (-105.9%)
|
0.09
est: 0.18 (-48.6%)
|
-0.09
est: 0.59 (-115.6%)
|
-1.23
est: 0.56 (-319.6%)
|
0.19
est: 0.70 (-72.9%)
|
0.44
est: 0.74 (-40.5%)
|
1.64
est: 0.83 (+97.0%)
|
-4.37
est: 0.09 (-4,782.2%)
|
-0.82
est: 0.05 (-1,857.1%)
|
-0.68
est: -0.01 (-13,500.0%)
|
-1.33
est: -0.06 (-2,273.9%)
|
-4.59
est: -6.02 (+23.7%)
|
-0.83
est: -0.28 (-199.6%)
|
-0.16
-0.16 – -0.16
+41.6% YoY
|
-0.16
-0.16 – -0.15
+3.2% YoY
|
-0.03
-0.05 – -0.02
+80.8% YoY
|
0.19
0.06 – 0.32
+733.3% YoY
|
0.29
0.29 – 0.29
+52.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 4.66M | 11.50% | — | — | 4.66M | — | HC | Delaware | 2024-10-23 | ↗ |
| 2 | (. | 3.10M | 8.44% | 2.98M | — | 3.10M | — | IA | Delaware | 2018-02-09 | ↗ |
| 3 | 30-0447847 | 2.70M | 7.00% | 2.65M | — | 2.70M | — | IA | Delaware Limited Partnership | 2022-02-08 | ↗ |
| 4 | The Vanguard Group - 23-1945930 | 2.56M | 6.63% | — | 31.3K | 2.50M | 60.0K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 5 | Victory Capital Management Inc. | 2.21M | 5.73% | 2.19M | — | 2.21M | — | IA | New York | 2022-02-01 | ↗ |
| 6 | Israel A. Englander | 2.06M | 5.10% | — | 2.06M | — | 2.06M | IN | Delaware | 2024-05-30 | ↗ |
| 7 | Millennium Group Management LLC | 2.06M | 5.10% | — | 2.06M | — | 2.06M | OO | Delaware | 2024-05-30 | ↗ |
| 8 | Millennium Management LLC | 2.06M | 5.10% | — | 2.06M | — | 2.06M | OO | Delaware | 2024-05-30 | ↗ |
| 9 | STATE STREET CORPORATION | 1.93M | 5.10% | — | 1.81M | — | 1.93M | HC | BOSTON, MASSACHUSETTS | 2021-02-05 | ↗ |
| 10 | Broadfin Capital, LLC | 1.47M | 3.96% | — | 1.47M | — | 1.47M | IA, OO | Delaware | 2017-02-13 | ↗ |
| 11 | Broadfin Healthcare Master Fund, Ltd. | 1.47M | 3.96% | — | 1.47M | — | 1.47M | CO | Delaware | 2017-02-13 | ↗ |
| 12 | Kevin Kotler | 1.47M | 3.96% | — | 1.47M | — | 1.47M | HC, IN | Delaware | 2017-02-13 | ↗ |
| 13 | RGM Capital, LLC | — | 0.00% | — | — | — | — | IA, OO | Delaware | 2018-02-14 | ↗ |
| 14 | Robert G. Moses | — | 0.00% | — | — | — | — | HC, IN | Delaware | 2018-02-14 | ↗ |
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 1.40M +1.4M (+100.0%) | 17.98B +18.0B (+100.0%) | 3.38% +3.382 pp | 16.98% +16.976 pp | USD12.84 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 3.86M +385.8K (+11.1%) | 49.57M +10.8M (+27.7%) | 9.32% +0.885 pp | 0.00% +0.000 pp | USD8.29 +54.9% | 6 qtrs — |
| 3 | POINT72 ASSET MANAGEMENT, L.P. | 2.83M +266.7K (+10.4%) | 36.28M +7.7M (+26.9%) | 6.82% +0.610 pp | 0.04% -0.007 pp | USD10.29 +24.8% | 4 qtrs — |
| 4 | SYSTEMATIC FINANCIAL MANAGEMENT LP | 2.50M -65.6K (-2.6%) | 32.16M +3.4M (+12.0%) | 6.05% -0.193 pp | 0.76% +0.060 pp | USD11.77 +9.1% | 51 qtrs — |
| 5 | VANGUARD GROUP INC | 2.44M +72.7K (+3.1%) | 31.29M +4.9M (+18.5%) | 5.89% +0.144 pp | 0.00% +0.000 pp | USD17.19 -25.3% | 84 qtrs — |
| 6 | KOTLER KEVIN | 1.71M +1.7M (+100.0%) | 22.00M +22.0M (+100.0%) | 4.14% +4.139 pp | 5.15% +5.146 pp | USD12.84 +0.0% | 1 qtrs NEW |
| 7 | ARMISTICE CAPITAL, LLC | 1.70M +64.0K (+3.9%) | 21.83M +3.6M (+19.4%) | 4.11% +0.133 pp | 0.26% -0.011 pp | USD9.00 +42.7% | 9 qtrs — |
| 8 | NUVEEN, LLC | 1.30M +373.1K (+40.5%) | 16.63M +6.3M (+61.5%) | 3.13% +0.889 pp | 0.00% +0.002 pp | USD10.38 +23.7% | 4 qtrs — |
| 9 | STATE STREET CORP | 1.27M +315.8K (+33.0%) | 16.34M +5.7M (+52.9%) | 3.07% +0.750 pp | 0.00% +0.000 pp | USD13.80 -7.0% | 51 qtrs — |
| 10 | ROYCE & ASSOCIATES LP | 1.27M +272.1K (+27.3%) | 16.27M +5.2M (+46.4%) | 3.06% +0.644 pp | 0.17% +0.054 pp | USD7.81 +64.4% | 8 qtrs — |
| 11 | SEGALL BRYANT & HAMILL, LLC | 1.20M -121.4K (-9.2%) | 15.38M +644.9K (+4.4%) | 2.89% -0.311 pp | 0.21% +0.012 pp | USD10.62 +20.9% | 33 qtrs — |
| 12 | BASTION ASSET MANAGEMENT INC. | 1.12M -145.8K (-11.5%) | 12.89M -557.1K (-4.1%) | 2.70% -0.369 pp | 7.11% -0.624 pp | USD9.95 +29.0% | 4 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 969.9K -6.7K (-0.7%) | 12.46M +1.5M (+14.2%) | 2.34% -0.030 pp | 0.00% +0.000 pp | USD15.49 -17.1% | 78 qtrs — |
| 14 | DIMENSIONAL FUND ADVISORS LP | 916.3K -239.3K (-20.7%) | 11.77M -1.1M (-8.8%) | 2.21% -0.594 pp | 0.00% 0.000 pp | USD12.12 +5.9% | 51 qtrs — |
| 15 | RENAISSANCE TECHNOLOGIES LLC | 843.1K -90.3K (-9.7%) | 10.83M +399.3K (+3.8%) | 2.04% -0.231 pp | 0.02% +0.003 pp | USD10.23 +25.5% | 70 qtrs — |
| 16 | MILLENNIUM MANAGEMENT LLC | 842.5K -950.6K (-53.0%) | 10.82M -9.2M (-46.0%) | 2.03% -2.320 pp | 0.00% -0.004 pp | USD9.77 +31.4% | 23 qtrs — |
| 17 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 752.9K +196.4K (+35.3%) | 9.67M +3.5M (+55.5%) | 1.82% +0.467 pp | 0.01% +0.002 pp | USD10.05 +27.8% | 9 qtrs — |
| 18 | UBS GROUP AG | 730.1K -372.4K (-33.8%) | 9.37M -2.9M (-23.9%) | 1.76% -0.914 pp | 0.00% 0.000 pp | USD10.17 +26.3% | 45 qtrs — |
| 19 | PARADIGM CAPITAL MANAGEMENT INC/NY | 678.2K +— (+0.0%) | 8.71M +1.1M (+15.0%) | 1.64% -0.009 pp | 0.37% +0.038 pp | USD11.17 +15.0% | 2 qtrs — |
| 20 | PHOCAS FINANCIAL CORP. | 606.3K -1.6K (-0.3%) | 7.78M +995.2K (+14.7%) | 1.46% -0.012 pp | 1.01% +0.132 pp | USD10.18 +26.1% | 4 qtrs — |
| 21 | PIER CAPITAL, LLC | 571.9K -91.4K (-13.8%) | 7.34M -65.5K (-0.9%) | 1.38% -0.230 pp | 1.17% +0.014 pp | USD9.54 +34.6% | 4 qtrs — |
| 22 | MANATUCK HILL PARTNERS, LLC | 425.0K +25.0K (+6.3%) | 5.46M +989.0K (+22.1%) | 1.03% +0.055 pp | 1.91% +0.431 pp | USD9.24 +39.0% | 7 qtrs — |
| 23 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 398.2K -50.3K (-11.2%) | 5.11M +102.6K (+2.0%) | 0.96% -0.128 pp | 0.01% -0.002 pp | USD9.35 +37.3% | 13 qtrs — |
| 24 | ESSEX INVESTMENT MANAGEMENT CO LLC | 360.5K +33.1K (+10.1%) | 4.63M +972.4K (+26.6%) | 0.87% +0.076 pp | 0.71% +0.146 pp | USD10.26 +25.1% | 4 qtrs — |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 332.9K -244.0 (-0.1%) | 4.27M +553.2K (+14.9%) | 0.80% -0.005 pp | 0.00% +0.000 pp | USD15.76 -18.5% | 67 qtrs — |
| 26 | GOLDMAN SACHS GROUP INC | 316.4K +46.3K (+17.1%) | 4.06M +1.0M (+34.6%) | 0.76% +0.108 pp | 0.00% +0.000 pp | USD12.73 +0.9% | 73 qtrs — |
| 27 | NORTHERN TRUST CORP | 305.1K -22.2K (-6.8%) | 3.92M +262.0K (+7.2%) | 0.74% -0.058 pp | 0.00% +0.000 pp | USD13.79 -6.9% | 51 qtrs — |
| 28 | TWO SIGMA INVESTMENTS, LP | 304.9K +164.1K (+116.6%) | 3.91M +2.3M (+149.0%) | 0.74% +0.395 pp | 0.01% +0.003 pp | USD11.88 +8.1% | 14 qtrs — |
| 29 | JANE STREET GROUP, LLC | 300.9K +201.4K (+202.5%) | 3.86M +2.8M (+247.7%) | 0.73% +0.485 pp | 0.00% +0.000 pp | USD11.93 +7.6% | 14 qtrs — |
| 30 | MARSHALL WACE, LLP | 284.7K -53.5K (-15.8%) | 3.66M -121.7K (-3.2%) | 0.69% -0.134 pp | 0.00% -0.001 pp | USD8.93 +43.8% | 13 qtrs — |
| 31 | MORGAN STANLEY | 269.1K +30.3K (+12.7%) | 3.46M +788.1K (+29.5%) | 0.65% +0.070 pp | 0.00% +0.000 pp | USD10.17 +26.3% | 50 qtrs — |
| 32 | FIRST EAGLE INVESTMENT MANAGEMENT, LLC | 267.7K -9.6K (-3.5%) | 3.44M +339.9K (+11.0%) | 0.65% -0.027 pp | 0.01% +0.000 pp | USD6.74 +90.5% | 7 qtrs — |
| 33 | TREXQUANT INVESTMENT LP | 263.1K +10.3K (+4.1%) | 3.38M +554.4K (+19.6%) | 0.64% +0.022 pp | 0.03% +0.001 pp | USD9.03 +42.2% | 14 qtrs — |
| 34 | ASSENAGON ASSET MANAGEMENT S.A. | 237.1K -56.1K (-19.1%) | 3.04M -231.2K (-7.1%) | 0.57% -0.140 pp | 0.00% 0.000 pp | USD9.45 +35.9% | 14 qtrs — |
| 35 | TWO SIGMA ADVISERS, LP | 230.0K +153.5K (+200.7%) | 2.95M +2.1M (+245.6%) | 0.56% +0.370 pp | 0.01% +0.004 pp | USD12.21 +5.2% | 51 qtrs — |
| 36 | QUBE RESEARCH & TECHNOLOGIES LTD | 229.3K -20.4K (-8.2%) | 2.94M +154.9K (+5.6%) | 0.55% -0.053 pp | 0.00% +0.000 pp | USD9.19 +39.7% | 13 qtrs — |
| 37 | AQR CAPITAL MANAGEMENT LLC | 225.6K +155.8K (+222.8%) | 2.90M +2.1M (+271.1%) | 0.55% +0.375 pp | 0.00% +0.001 pp | USD11.60 +10.7% | 44 qtrs — |
| 38 | SEI INVESTMENTS CO | 222.1K +222.1K (+100.0%) | 2.85M +2.9M (+100.0%) | 0.54% +0.537 pp | 0.00% +0.003 pp | USD12.84 +0.0% | 1 qtrs NEW |
| 39 | KENNEDY CAPITAL MANAGEMENT LLC | 193.3K -1.2K (-0.6%) | 2.48M +309.0K (+14.2%) | 0.47% -0.006 pp | 0.05% +0.005 pp | USD9.89 +29.8% | 19 qtrs — |
| 40 | ACADIAN ASSET MANAGEMENT LLC | 190.3K +58.7K (+44.6%) | 2.44M +973.0K (+66.3%) | 0.46% +0.140 pp | 0.00% +0.001 pp | USD11.69 +9.8% | 2 qtrs — |
| 41 | PANAGORA ASSET MANAGEMENT INC | 184.1K +28.4K (+18.3%) | 2.36M +625.1K (+35.9%) | 0.44% +0.067 pp | 0.01% +0.001 pp | USD9.82 +30.8% | 67 qtrs — |
| 42 | MOORE CAPITAL MANAGEMENT, LP | 166.2K -71.7K (-30.1%) | 2.13M -523.6K (-19.7%) | 0.40% -0.176 pp | 0.03% -0.006 pp | USD10.49 +22.4% | 4 qtrs — |
| 43 | WHITE PINE CAPITAL LLC | 150.5K +45.4K (+43.2%) | 1.93M +758.3K (+64.6%) | 0.36% +0.108 pp | 0.53% +0.196 pp | USD10.61 +21.0% | 6 qtrs — |
| 44 | BRINKER CAPITAL INVESTMENTS, LLC | 141.8K -4.8K (-3.2%) | 1.82M +183.7K (+11.2%) | 0.34% -0.013 pp | 0.01% +0.001 pp | USD10.32 +24.4% | 22 qtrs — |
| 45 | BANK OF AMERICA CORP /DE/ | 138.9K -206.4K (-59.8%) | 1.78M -2.1M (-53.8%) | 0.34% -0.503 pp | 0.00% 0.000 pp | USD10.25 +25.3% | 52 qtrs — |
| 46 | D.A. DAVIDSON & CO. | 136.3K +136.3K (+100.0%) | 1.75M +1.8M (+100.0%) | 0.33% +0.329 pp | 0.01% +0.011 pp | USD12.84 +0.0% | 1 qtrs NEW |
| 47 | FMR LLC | 128.4K +30.3K (+30.9%) | 1.65M +552.7K (+50.4%) | 0.31% +0.072 pp | 0.00% +0.000 pp | USD10.08 +27.4% | 30 qtrs — |
| 48 | AMERIPRISE FINANCIAL INC | 123.3K -4.2K (-3.3%) | 1.58M +159.6K (+11.2%) | 0.30% -0.012 pp | 0.00% +0.000 pp | USD14.96 -14.2% | 45 qtrs — |
| 49 | BANK OF NEW YORK MELLON CORP | 119.2K -750.0 (-0.6%) | 1.53M +190.7K (+14.2%) | 0.29% -0.003 pp | 0.00% +0.000 pp | USD15.14 -15.2% | 66 qtrs — |
| 50 | LEGATO CAPITAL MANAGEMENT LLC | 116.6K +22.2K (+23.5%) | 1.50M +442.5K (+42.0%) | 0.28% +0.052 pp | 0.13% +0.014 pp | USD10.51 +22.2% | 4 qtrs — |
| 51 | INVESCO LTD. | 114.5K -12.9K (-10.1%) | 1.47M +47.3K (+3.3%) | 0.28% -0.033 pp | 0.00% +0.000 pp | USD11.51 +11.6% | 57 qtrs — |
| 52 | ROYAL BANK OF CANADA | 110.0K -4.9K (-4.3%) | 1.41M +129.0K (+10.0%) | 0.27% -0.014 pp | 0.00% +0.000 pp | USD9.32 +37.8% | 51 qtrs — |
| 53 | GLOBEFLEX CAPITAL L P | 104.2K +— (+0.0%) | 1.34M +173.9K (+15.0%) | 0.25% -0.001 pp | 0.20% +0.026 pp | USD7.78 +65.0% | 6 qtrs — |
| 54 | AMERICAN CENTURY COMPANIES INC | 99.9K +2.0K (+2.1%) | 1.28M +189.5K (+17.3%) | 0.24% +0.004 pp | 0.00% +0.000 pp | USD8.69 +47.8% | 11 qtrs — |
| 55 | EAM INVESTORS, LLC | 95.3K +95.3K (+100.0%) | 1.22M +1.2M (+100.0%) | 0.23% +0.230 pp | 0.14% +0.136 pp | USD12.84 +0.0% | 4 qtrs — |
| 56 | BARCLAYS PLC | 92.7K +9.1K (+10.9%) | 1.19M +539.9K (+83.0%) | 0.22% +0.021 pp | 0.00% +0.000 pp | USD10.02 +28.1% | 51 qtrs — |
| 57 | NEW YORK STATE COMMON RETIREMENT FUND | 89.6K -607.0 (-0.7%) | 1.15M +142.8K (+14.2%) | 0.22% -0.003 pp | 0.00% +0.000 pp | USD10.70 +20.0% | 45 qtrs — |
| 58 | VERITION FUND MANAGEMENT LLC | 77.8K +31.3K (+67.4%) | 998.8K +479.9K (+92.5%) | 0.19% +0.075 pp | 0.00% +0.002 pp | USD11.10 +15.7% | 13 qtrs — |
| 59 | Y-INTERCEPT (HONG KONG) LTD | 68.0K +4.0K (+6.3%) | 872.5K +158.6K (+22.2%) | 0.16% +0.009 pp | 0.02% +0.002 pp | USD10.04 +27.9% | 10 qtrs — |
| 60 | ENVESTNET ASSET MANAGEMENT INC | 63.9K -3.0K (-4.5%) | 820.5K +73.4K (+9.8%) | 0.15% -0.008 pp | 0.00% +0.000 pp | USD9.55 +34.5% | 36 qtrs — |
| 61 | HSBC HOLDINGS PLC | 62.4K +35.1K (+128.4%) | 801.1K +501.8K (+167.7%) | 0.15% +0.084 pp | 0.00% +0.000 pp | USD11.77 +9.1% | 16 qtrs — |
| 62 | MOODY NATIONAL BANK TRUST DIVISION | 55.8K +— (+0.0%) | 716.2K +93.2K (+15.0%) | 0.13% -0.001 pp | 0.07% +0.016 pp | USD8.93 +43.8% | 12 qtrs — |
| 63 | RHUMBLINE ADVISERS | 52.6K -7.6K (-12.6%) | 675.5K +3.3K (+0.5%) | 0.13% -0.019 pp | 0.00% +0.000 pp | USD15.38 -16.5% | 51 qtrs — |
| 64 | STONEX GROUP INC. | 52.5K -1.4K (-2.6%) | 674.7K +71.8K (+11.9%) | 0.13% -0.004 pp | 0.03% +0.003 pp | USD9.16 +40.2% | 5 qtrs — |
| 65 | CITADEL ADVISORS LLC | 50.9K +50.9K (+100.0%) | 653.3K +653.3K (+100.0%) | 0.12% +0.123 pp | 0.00% +0.000 pp | USD12.84 +0.0% | 1 qtrs NEW |
| 66 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 49.8K -16.8K (-25.2%) | 631.1K -112.5K (-15.1%) | 0.12% -0.042 pp | 0.00% 0.000 pp | USD13.73 -6.5% | 29 qtrs — |
| 67 | FRANKLIN RESOURCES INC | 48.4K +1.1K (+2.3%) | 620.9K +92.8K (+17.6%) | 0.12% +0.002 pp | 0.00% +0.000 pp | USD7.20 +78.3% | 8 qtrs — |
| 68 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 47.4K +31.8K (+204.7%) | 608.6K +434.9K (+250.3%) | 0.11% +0.077 pp | 0.00% +0.003 pp | USD12.29 +4.5% | 2 qtrs — |
| 69 | DYNAMIC TECHNOLOGY LAB PRIVATE LTD | 46.2K +46.2K (+100.0%) | 593.0K +593.0K (+100.0%) | 0.11% +0.112 pp | 0.13% +0.134 pp | USD12.84 +0.0% | 7 qtrs — |
| 70 | WELLS FARGO & COMPANY/MN | 45.7K +16.3K (+55.2%) | 587.1K +258.0K (+78.4%) | 0.11% +0.039 pp | 0.00% +0.000 pp | USD10.64 +20.7% | 57 qtrs — |
| 71 | GALLAGHER FIDUCIARY ADVISORS, LLC | 44.9K +4.1K (+10.0%) | 576.5K +120.4K (+26.4%) | 0.11% +0.009 pp | 0.02% +0.002 pp | USD11.32 +13.4% | 2 qtrs — |
| 72 | ATRIA INVESTMENTS, INC | 44.9K +4.1K (+10.0%) | 576.5K +120.4K (+26.4%) | 0.11% +0.009 pp | 0.01% +0.001 pp | USD11.32 +13.4% | 2 qtrs — |
| 73 | PRICE T ROWE ASSOCIATES INC /MD/ | 44.3K +2.3K (+5.4%) | 569.0K +99.0K (+21.1%) | 0.11% +0.005 pp | 0.00% +0.000 pp | USD12.85 -0.1% | 35 qtrs — |
| 74 | STRS OHIO | 41.6K +— (+0.0%) | 534.1K +69.5K (+15.0%) | 0.10% -0.001 pp | 0.00% +0.000 pp | USD5.75 +123.3% | 10 qtrs — |
| 75 | SQUAREPOINT OPS LLC | 41.1K -123.3K (-75.0%) | 527.8K -1.3M (-71.3%) | 0.10% -0.300 pp | 0.00% -0.001 pp | USD10.24 +25.4% | 5 qtrs — |
| 76 | XTX TOPCO LTD | 40.8K +16.7K (+69.6%) | 524.0K +255.2K (+94.9%) | 0.10% +0.040 pp | 0.01% 0.000 pp | USD11.86 +8.3% | 2 qtrs — |
| 77 | QUANTINNO CAPITAL MANAGEMENT LP | 37.9K +8.5K (+29.1%) | 486.2K +158.6K (+48.4%) | 0.09% +0.020 pp | 0.00% +0.000 pp | USD10.88 +18.0% | 3 qtrs — |
| 78 | ALLIANCEBERNSTEIN L.P. | 37.2K -18.9K (-33.7%) | 477.6K -149.0K (-23.8%) | 0.09% -0.046 pp | 0.00% +0.000 pp | USD12.62 +1.7% | 61 qtrs — |
| 79 | QUADRATURE CAPITAL LTD | 36.1K +36.1K (+100.0%) | 463.2K +463.2K (+100.0%) | 0.09% +0.087 pp | 0.00% +0.005 pp | USD12.84 +0.0% | 1 qtrs NEW |
| 80 | DEUTSCHE BANK AG\ | 35.6K +2.0K (+5.9%) | 456.9K +81.7K (+21.8%) | 0.09% +0.004 pp | 0.00% +0.000 pp | USD9.92 +29.4% | 50 qtrs — |
| 81 | CANADA PENSION PLAN INVESTMENT BOARD | 35.2K +35.2K (+100.0%) | 452.0K +452.0K (+100.0%) | 0.09% +0.085 pp | 0.00% +0.000 pp | USD12.84 +0.0% | 1 qtrs NEW |
| 82 | QUEST PARTNERS LLC | 33.7K +10.8K (+47.3%) | 432.4K +177.0K (+69.3%) | 0.08% +0.026 pp | 0.02% +0.008 pp | USD11.71 +9.6% | 6 qtrs — |
| 83 | HILLSDALE INVESTMENT MANAGEMENT INC. | 33.2K +— (+0.0%) | 426.3K +55.4K (+15.0%) | 0.08% 0.000 pp | 0.01% +0.001 pp | USD11.13 +15.4% | 4 qtrs — |
| 84 | SG AMERICAS SECURITIES, LLC | 29.9K +15.3K (+104.6%) | 384.0K +221.0K (+135.6%) | 0.07% +0.037 pp | 0.00% 0.000 pp | USD12.02 +6.8% | 6 qtrs — |
| 85 | GSA CAPITAL PARTNERS LLP | 29.6K +29.6K (+100.0%) | 381.0K +381.0K (+100.0%) | 0.07% +0.072 pp | 0.03% +0.033 pp | USD12.84 +0.0% | 21 qtrs — |
| 86 | STATE OF WISCONSIN INVESTMENT BOARD | 28.6K -3.5K (-10.9%) | 367.7K +8.7K (+2.4%) | 0.07% -0.009 pp | 0.00% +0.000 pp | USD9.83 +30.6% | 12 qtrs — |
| 87 | VERSOR INVESTMENTS LP | 24.1K +24.1K (+100.0%) | 309.4K +309.4K (+100.0%) | 0.06% +0.058 pp | 0.05% +0.048 pp | USD12.84 +0.0% | 1 qtrs NEW |
| 88 | SKOPOS LABS, INC. | 23.2K +23.2K (+100.0%) | 298.0K +298.0K (+100.0%) | 0.06% +0.056 pp | 0.01% +0.014 pp | USD12.84 +0.0% | 4 qtrs — |
| 89 | R SQUARED LTD | 23.2K +4.1K (+21.3%) | 298.0K +84.3K (+39.5%) | 0.06% +0.010 pp | 0.14% +0.047 pp | USD11.46 +12.0% | 2 qtrs — |
| 90 | D. E. SHAW & CO., INC. | 23.1K +3.6K (+18.4%) | 297.2K +78.9K (+36.1%) | 0.06% +0.008 pp | 0.00% +0.000 pp | USD10.41 +23.3% | 67 qtrs — |
| 91 | CONCURRENT INVESTMENT ADVISORS, LLC | 21.7K -7.8K (-26.6%) | 278.1K -51.4K (-15.6%) | 0.05% -0.019 pp | 0.00% -0.003 pp | USD6.56 +95.7% | 9 qtrs — |
| 92 | METLIFE INVESTMENT MANAGEMENT, LLC | 21.6K +— (+0.0%) | 277.5K +36.1K (+15.0%) | 0.05% 0.000 pp | 0.00% +0.000 pp | USD12.76 +0.6% | 33 qtrs — |
| 93 | ATOM INVESTORS LP | 21.2K -14.7K (-41.0%) | 271.6K -128.9K (-32.2%) | 0.05% -0.036 pp | 0.02% -0.009 pp | USD10.40 +23.5% | 8 qtrs — |
| 94 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 18.2K +439.0 (+2.5%) | 234.3K +35.4K (+17.8%) | 0.04% +0.001 pp | 0.00% +0.000 pp | USD6.32 +103.2% | 7 qtrs — |
| 95 | INTECH INVESTMENT MANAGEMENT LLC | 17.5K +— (+0.0%) | 224.9K +29.3K (+15.0%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD9.21 +39.4% | 5 qtrs — |
| 96 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 17.4K -33.7K (-65.9%) | 223.4K -347.4K (-60.9%) | 0.04% -0.082 pp | 0.00% +0.000 pp | USD10.86 +18.2% | 3 qtrs — |
| 97 | ALAN B. LANCZ & ASSOCIATES, INC. | 16.4K +— (+0.0%) | 209.9K +27.3K (+15.0%) | 0.04% 0.000 pp | 0.18% +0.019 pp | USD7.52 +70.7% | 7 qtrs — |
| 98 | PNC FINANCIAL SERVICES GROUP, INC. | 16.3K +78.0 (+0.5%) | 209.6K +28.1K (+15.5%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD15.10 -15.0% | 51 qtrs — |
| 99 | JPMORGAN CHASE & CO | 16.3K -658.0 (-3.9%) | 208.7K +19.8K (+10.5%) | 0.04% -0.002 pp | 0.00% +0.000 pp | USD10.91 +17.7% | 40 qtrs — |
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.56% | 122.2K | 0.20% |
| 2 | State Street SPDR S&P Health Care Equipment ETF XHE | 0.50% | 749.6K | 0.35% |
| 3 | iShares Micro-Cap ETF IWC | 0.11% | 1.60M | 0.60% |
| 4 | Vanguard U.S. Multifactor ETF VFMF | 0.11% | 685.1K | 0.18% |
| 5 | State Street SPDR US Small Cap Low Volatility Index ETF SMLV | 0.10% | 247.0K | 0.12% |
| 6 | iShares U.S. Medical Devices ETF IHI | 0.08% | 2.47M | 0.38% |
| 7 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.07% | 750.1K | 0.20% |
| 8 | iShares US Medical Devices UCITS ETF USD UMDV.AS | 0.05% | 92.2K | 0.25% |
| 9 | Innovator U.S. Small Cap Managed Floor ETF RFLR | 0.05% | 44.3K | 0.89% |
| 10 | Avantis U.S. Small Cap Equity ETF AVSC | 0.04% | 1.15M | 0.25% |
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-21 | Weiss Lawrence T | Officer | P-Purchase | A | Common Stock | 10,000 | 11.81 | 118.1K | 93,597 | D | ↗ |
| 2025-10-13 | Trowbridge Stephen A | Officer | P-Purchase | A | Common Stock | 890 | 11.16 | 9.9K | 256,629 | D | ↗ |
| 2025-10-09 | Clemmer James C | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 11.15 | 111.5K | 882,529 | D | ↗ |
| 2025-07-21 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 667 | 8.99 | 6.0K | 255,739 | D | ↗ |
| 2025-07-21 | Nighan Warren JR | Officer | F-InKind | D | Common Stock | 277 | 8.99 | 2.5K | 69,903 | D | ↗ |
| 2025-07-21 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 395 | 8.99 | 3.6K | 92,297 | D | ↗ |
| 2025-07-20 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 717 | 8.69 | 6.2K | 256,406 | D | ↗ |
| 2025-07-20 | Piccinini Laura | Officer | F-InKind | D | Common Stock | 616 | 8.69 | 5.4K | 66,756 | D | ↗ |
| 2025-07-20 | Nighan Warren JR | Officer | F-InKind | D | Common Stock | 251 | 8.69 | 2.2K | 70,180 | D | ↗ |
| 2025-07-20 | Clemmer James C | Director / Officer | F-InKind | D | Common Stock | 3,673 | 8.99 | 33.0K | 872,529 | D | ↗ |
| 2025-07-20 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 359 | 8.69 | 3.1K | 92,692 | D | ↗ |
| 2025-07-19 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 2,585 | 8.69 | 22.5K | 257,123 | D | ↗ |
| 2025-07-19 | Piccinini Laura | Officer | F-InKind | D | Common Stock | 1,983 | 8.69 | 17.2K | 67,372 | D | ↗ |
| 2025-07-19 | Nighan Warren JR | Officer | F-InKind | D | Common Stock | 735 | 8.69 | 6.4K | 70,431 | D | ↗ |
| 2025-07-19 | Clemmer James C | Director / Officer | F-InKind | D | Common Stock | 344 | 8.69 | 3.0K | 887,491 | D | ↗ |
| 2025-07-19 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 1,025 | 8.69 | 8.9K | 93,051 | D | ↗ |
| 2025-07-17 | Piccinini Laura | Officer | F-InKind | D | Common Stock | 3,074 | 8.74 | 26.9K | 69,355 | D | ↗ |
| 2025-07-16 | Weiss Lawrence T | Officer | A-Award | A | Performance Right | 30,900 | 0.00 | — | 30,900 | D | ↗ |
| 2025-07-16 | Trowbridge Stephen A | Officer | A-Award | A | Performance Right | 86,997 | 0.00 | — | 86,997 | D | ↗ |
| 2025-07-16 | Tarnoff Michael E | Director | A-Award | A | Common Stock | 17,675 | 0.00 | — | 83,378 | D | ↗ |
| 2025-07-16 | REED JAN STERN | Director | A-Award | A | Common Stock | 17,675 | 0.00 | — | 105,034 | D | ↗ |
| 2025-07-16 | Piccinini Laura | Officer | A-Award | A | Performance Right | 32,423 | 0.00 | — | 32,423 | D | ↗ |
| 2025-07-16 | Nighan Warren JR | Officer | A-Award | A | Common Stock | 29,349 | 0.00 | — | 71,166 | D | ↗ |
| 2025-07-16 | Licitra Karen A | Director | A-Award | A | Common Stock | 17,675 | 0.00 | — | 90,435 | D | ↗ |
| 2025-07-16 | JOHNSON WESLEY | Director | A-Award | A | Common Stock | 17,675 | 0.00 | — | 143,538 | D | ↗ |
| 2025-07-16 | DONNELLY HOWARD W | Director | A-Award | A | Common Stock | 17,675 | 0.00 | — | 167,051 | D | ↗ |
| 2025-07-16 | Clemmer James C | Director / Officer | A-Award | A | Performance Right | 206,253 | 0.00 | — | 206,253 | D | ↗ |
| 2025-07-16 | Campbell Chad Thomas | Officer | A-Award | A | Performance Right | 26,268 | 0.00 | — | 26,268 | D | ↗ |
| 2025-07-16 | Burgess Lorinda | Director | A-Award | A | Common Stock | 17,675 | 0.00 | — | 55,257 | D | ↗ |
| 2025-07-16 | Auen Eileen O'Shea | Director | A-Award | A | Common Stock | 17,675 | 0.00 | — | 104,718 | D | ↗ |
| 2025-01-16 | Nighan Warren JR | Officer | S-Sale | D | Common Stock | 4,060 | 12.31 | 50.0K | 41,817 | D | ↗ |
| 2024-12-02 | Weiss Lawrence T | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-10 | Nighan Warren JR | Officer | P-Purchase | A | Common Stock | 100 | 6.08 | 608.00 | 45,877 | D | ↗ |
| 2024-10-08 | Trowbridge Stephen A | Officer | P-Purchase | A | Common Stock | 1,700 | 5.86 | 10.0K | 172,711 | D | ↗ |
| 2024-10-07 | Nighan Warren JR | Officer | P-Purchase | A | Common Stock | 768 | 6.09 | 4.7K | 45,777 | D | ↗ |
| 2024-10-07 | Clemmer James C | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 6.03 | 120.6K | 681,582 | D | ↗ |
| 2024-07-21 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 667 | 7.13 | 4.8K | 166,470 | — | ↗ |
| 2024-07-21 | Piccinini Laura | Officer | F-InKind | D | Common Stock | 413 | 7.13 | 2.9K | 38,052 | — | ↗ |
| 2024-07-21 | Nighan Warren JR | Officer | F-InKind | D | Common Stock | 277 | 7.13 | 2.0K | 40,998 | — | ↗ |
| 2024-07-21 | Clemmer James C | Director / Officer | F-InKind | D | Common Stock | 3,372 | 7.13 | 24.0K | 634,033 | — | ↗ |
| 2024-07-21 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 395 | 7.13 | 2.8K | 63,587 | — | ↗ |
| 2024-07-20 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 717 | 7.13 | 5.1K | 167,137 | — | ↗ |
| 2024-07-20 | Piccinini Laura | Officer | F-InKind | D | Common Stock | 616 | 7.13 | 4.4K | 38,465 | — | ↗ |
| 2024-07-20 | Nighan Warren JR | Officer | F-InKind | D | Common Stock | 251 | 7.13 | 1.8K | 41,275 | — | ↗ |
| 2024-07-20 | Clemmer James C | Director / Officer | F-InKind | D | Common Stock | 2,982 | 7.13 | 21.3K | 637,405 | — | ↗ |
| 2024-07-20 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 359 | 7.13 | 2.6K | 63,982 | — | ↗ |
| 2024-07-19 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 2,585 | 7.18 | 18.6K | 171,011 | — | ↗ |
| 2024-07-19 | Piccinini Laura | Officer | F-InKind | D | Common Stock | 1,983 | 7.18 | 14.2K | 39,081 | — | ↗ |
| 2024-07-19 | Nighan Warren JR | Officer | F-InKind | D | Common Stock | 735 | 7.18 | 5.3K | 41,526 | — | ↗ |
| 2024-07-19 | Clemmer James C | Director / Officer | A-Award | A | Common Stock | 3,817 | 0.00 | — | 640,387 | — | ↗ |
| 2024-07-19 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 1,025 | 7.18 | 7.4K | 64,341 | — | ↗ |
| 2024-07-17 | Trowbridge Stephen A | Officer | A-Award | A | Performance Right | 77,905 | 0.00 | — | 77,905 | — | ↗ |
| 2024-07-17 | Tarnoff Michael E | Director | A-Award | A | Common Stock | 20,541 | 0.00 | — | 65,703 | — | ↗ |
| 2024-07-17 | REED JAN STERN | Director | A-Award | A | Common Stock | 20,541 | 0.00 | — | 87,359 | — | ↗ |
| 2024-07-17 | Piccinini Laura | Officer | A-Award | A | Performance Right | 30,428 | 0.00 | — | 30,428 | — | ↗ |
| 2024-07-17 | Nighan Warren JR | Officer | A-Award | A | Performance Right | 23,952 | 0.00 | — | 23,952 | — | ↗ |
| 2024-07-17 | Licitra Karen A | Director | A-Award | A | Common Stock | 20,541 | 0.00 | — | 72,760 | — | ↗ |
| 2024-07-17 | JOHNSON WESLEY | Director | A-Award | A | Common Stock | 20,541 | 0.00 | — | 125,863 | — | ↗ |
| 2024-07-17 | DONNELLY HOWARD W | Director | A-Award | A | Common Stock | 20,541 | 0.00 | — | 149,376 | — | ↗ |
| 2024-07-17 | Clemmer James C | Director / Officer | A-Award | A | Common Stock | 105,811 | 0.00 | — | 644,877 | — | ↗ |
| 2024-07-17 | Campbell Chad Thomas | Officer | A-Award | A | Common Stock | 12,350 | 0.00 | — | 65,366 | — | ↗ |
| 2024-07-17 | Burgess Lorinda | Director | A-Award | A | Common Stock | 20,541 | 0.00 | — | 37,582 | — | ↗ |
| 2024-07-17 | Auen Eileen O'Shea | Director | A-Award | A | Common Stock | 20,541 | 0.00 | — | 87,043 | — | ↗ |
| 2024-04-08 | Clemmer James C | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 6.70 | 67.0K | 539,066 | — | ↗ |
| 2024-02-29 | Trowbridge Stephen A | Officer | A-Award | A | Common Stock | 1,927 | 4.67 | 9.0K | 128,901 | — | ↗ |
| 2023-07-21 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 667 | 8.65 | 5.8K | 114,595 | — | ↗ |
| 2023-07-21 | Piccinini Laura | Officer | F-InKind | D | Common Stock | 413 | 8.65 | 3.6K | 19,093 | — | ↗ |
| 2023-07-21 | Helsel Dave | Officer | F-InKind | D | Common Stock | 365 | 8.65 | 3.2K | 28,289 | — | ↗ |
| 2023-07-21 | Clemmer James C | Director / Officer | F-InKind | D | Common Stock | 3,372 | 8.65 | 29.2K | 529,066 | — | ↗ |
| 2023-07-21 | Centea Scott | Officer | F-InKind | D | Common Stock | 255 | 8.65 | 2.2K | 58,128 | — | ↗ |
| 2023-07-21 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 395 | 8.65 | 3.4K | 47,509 | — | ↗ |
| 2023-07-20 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 717 | 8.74 | 6.3K | 115,262 | — | ↗ |
| 2023-07-20 | Piccinini Laura | Officer | F-InKind | D | Common Stock | 616 | 8.74 | 5.4K | 19,506 | — | ↗ |
| 2023-07-20 | Helsel Dave | Officer | F-InKind | D | Common Stock | 332 | 8.74 | 2.9K | 28,654 | — | ↗ |
| 2023-07-20 | Clemmer James C | Director / Officer | F-InKind | D | Common Stock | 2,982 | 8.74 | 26.1K | 532,438 | — | ↗ |
| 2023-07-20 | Centea Scott | Officer | F-InKind | D | Common Stock | 333 | 8.74 | 2.9K | 58,383 | — | ↗ |
| 2023-07-20 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 359 | 8.74 | 3.1K | 47,904 | — | ↗ |
| 2023-07-19 | Trowbridge Stephen A | Officer | A-Award | A | Common Stock | 28,691 | 0.00 | — | 115,979 | — | ↗ |
| 2023-07-19 | Tarnoff Michael E | Director | A-Award | A | Common Stock | 17,041 | 0.00 | — | 45,162 | — | ↗ |
| 2023-07-19 | REED JAN STERN | Director | A-Award | A | Common Stock | 17,041 | 0.00 | — | 66,818 | — | ↗ |
| 2023-07-19 | Piccinini Laura | Officer | A-Award | A | Performance Right | 28,336 | 0.00 | — | 28,336 | — | ↗ |
| 2023-07-19 | Meteny Dennis S | Director | A-Award | A | Common Stock | 17,041 | 0.00 | — | 140,019 | — | ↗ |
| 2023-07-19 | Licitra Karen A | Director | A-Award | A | Common Stock | 17,041 | 0.00 | — | 52,219 | — | ↗ |
| 2023-07-19 | JOHNSON WESLEY | Director | A-Award | A | Common Stock | 17,041 | 0.00 | — | 105,322 | — | ↗ |
| 2023-07-19 | Helsel Dave | Officer | A-Award | A | Common Stock | 10,789 | 0.00 | — | 28,986 | — | ↗ |
| 2023-07-19 | DONNELLY HOWARD W | Director | A-Award | A | Common Stock | 17,041 | 0.00 | — | 128,835 | — | ↗ |
| 2023-07-19 | Clemmer James C | Director / Officer | A-Award | A | Performance Right | 184,361 | 0.00 | — | 184,361 | — | ↗ |
| 2023-07-19 | Centea Scott | Officer | A-Award | A | Common Stock | 10,588 | 0.00 | — | 58,716 | — | ↗ |
| 2023-07-19 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 3,103 | 8.92 | 27.7K | 53,016 | — | ↗ |
| 2023-07-19 | Burgess Lorinda | Director | A-Award | A | Common Stock | 17,041 | 0.00 | — | 17,041 | — | ↗ |
| 2023-07-19 | Auen Eileen O'Shea | Director | A-Award | A | Common Stock | 17,041 | 0.00 | — | 66,502 | — | ↗ |
| 2023-07-17 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 376 | 9.56 | 3.6K | 87,288 | — | ↗ |
| 2023-07-17 | Helsel Dave | Officer | F-InKind | D | Common Stock | 313 | 9.56 | 3.0K | 18,197 | — | ↗ |
| 2023-07-17 | Clemmer James C | Director / Officer | F-InKind | D | Common Stock | 2,262 | 9.56 | 21.6K | 443,239 | — | ↗ |
| 2023-07-17 | Centea Scott | Officer | F-InKind | D | Common Stock | 351 | 9.56 | 3.4K | 48,128 | — | ↗ |
| 2023-07-17 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 279 | 9.56 | 2.7K | 36,879 | — | ↗ |
| 2023-07-14 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 1,362 | 9.63 | 13.1K | 87,664 | — | ↗ |
| 2023-07-14 | Helsel Dave | Officer | F-InKind | D | Common Stock | 679 | 9.63 | 6.5K | 18,510 | — | ↗ |
| 2023-07-14 | Clemmer James C | Director / Officer | F-InKind | D | Common Stock | 4,906 | 9.63 | 47.2K | 445,501 | — | ↗ |
| 2023-07-14 | Centea Scott | Officer | F-InKind | D | Common Stock | 517 | 9.63 | 5.0K | 48,479 | — | ↗ |
| 2023-07-14 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 596 | 9.63 | 5.7K | 37,158 | — | ↗ |
| 2023-06-01 | Piccinini Laura | Officer | F-InKind | D | Common Stock | 1,400 | 9.64 | 13.5K | 5,954 | — | ↗ |
| 2023-02-03 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 555 | 13.43 | 7.5K | 89,026 | — | ↗ |
| 2023-02-01 | ROSENZWEIG RICHARD C | Officer | F-InKind | D | Common Stock | 1,137 | 13.36 | 15.2K | 15,730 | — | ↗ |
| 2023-01-31 | Helsel Dave | Officer | S-Sale | D | Common Stock | 4,633 | 12.95 | 60.0K | 19,189 | — | ↗ |
| 2022-10-12 | Trowbridge Stephen A | Officer | P-Purchase | A | Common Stock | 1,083 | 13.82 | 15.0K | 89,581 | — | ↗ |
| 2022-10-10 | Clemmer James C | Officer | P-Purchase | A | Common Stock | 10,000 | 15.00 | 150.0K | 450,407 | — | ↗ |
| 2022-07-29 | Helsel Dave | Officer | S-Sale | D | Common Stock | 5,000 | 22.44 | 112.2K | 23,822 | — | ↗ |
| 2022-07-20 | Trowbridge Stephen A | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 18,650 | 0.00 | — | 18,650 | — | ↗ |
| 2022-07-20 | Tarnoff Michael E | Director | A-Award | A | Common Stock | 7,060 | 0.00 | — | 28,121 | — | ↗ |
| 2022-07-20 | ROSENZWEIG RICHARD C | Officer | A-Award | A | Performance Right | 7,925 | 0.00 | — | 7,925 | — | ↗ |
| 2022-07-20 | REED JAN STERN | Director | A-Award | A | Common Stock | 7,060 | 0.00 | — | 49,777 | — | ↗ |
| 2022-07-20 | Piccinini Laura | Officer | A-Award | A | Common Stock | 4,402 | 0.00 | — | 7,354 | — | ↗ |
| 2022-07-20 | Nighan Warren JR | Officer | A-Award | A | Performance Right | 6,852 | 0.00 | — | 6,852 | — | ↗ |
| 2022-07-20 | Meteny Dennis S | Director | A-Award | A | Common Stock | 7,060 | 0.00 | — | 122,978 | — | ↗ |
| 2022-07-20 | Licitra Karen A | Director | A-Award | A | Common Stock | 7,060 | 0.00 | — | 35,178 | — | ↗ |
| 2022-07-20 | JOHNSON WESLEY | Director | A-Award | A | Common Stock | 7,060 | 0.00 | — | 88,281 | — | ↗ |
| 2022-07-20 | Helsel Dave | Officer | A-Award | A | Common Stock | 3,691 | 0.00 | — | 28,822 | — | ↗ |
| 2022-07-20 | DONNELLY HOWARD W | Director | A-Award | A | Common Stock | 7,060 | 0.00 | — | 111,794 | — | ↗ |
| 2022-07-20 | Clemmer James C | Officer | A-Award | A | Common Stock | 33,094 | 0.00 | — | 440,407 | — | ↗ |
| 2022-07-20 | Centea Scott | Officer | A-Award | A | Common Stock | 3,705 | 0.00 | — | 48,996 | — | ↗ |
| 2022-07-20 | Campbell Chad Thomas | Officer | A-Award | A | Performance Right | 7,974 | 0.00 | — | 7,974 | — | ↗ |
| 2022-07-20 | Auen Eileen O'Shea | Director | A-Award | A | Common Stock | 7,060 | 0.00 | — | 49,461 | — | ↗ |
| 2022-07-15 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 12,398 | 21.32 | 264.3K | 80,537 | — | ↗ |
| 2022-07-15 | JOHNSON WESLEY | Director | M-Exempt | D | Non- Qualified Stock Option (right to buy) | 6,022 | 15.95 | 96.1K | 0 | — | ↗ |
| 2022-07-12 | Meteny Dennis S | Director | M-Exempt | A | Common Stock | 6,022 | 15.95 | 96.1K | 120,716 | — | ↗ |
| 2022-07-07 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 1,509 | 20.54 | 31.0K | 78,177 | — | ↗ |
| 2022-07-07 | Nighan Warren JR | Officer | M-Exempt | D | Performance Right | 6,452 | 0.00 | — | 0 | — | ↗ |
| 2022-07-07 | Helsel Dave | Officer | M-Exempt | D | Performance Right | 6,945 | 0.00 | — | 0 | — | ↗ |
| 2022-07-07 | Clemmer James C | Officer | M-Exempt | D | Performance Right | 50,139 | 0.00 | — | 0 | — | ↗ |
| 2022-07-07 | Campbell Chad Thomas | Officer | M-Exempt | D | Performance Right | 6,195 | 0.00 | — | 0 | — | ↗ |
| 2022-04-28 | Helsel Dave | Officer | S-Sale | D | Common Stock | 3,513 | 22.44 | 78.8K | 22,874 | — | ↗ |
| 2022-04-20 | DONNELLY HOWARD W | Director | M-Exempt | A | Common Stock | 6,022 | 15.95 | 96.1K | 104,734 | — | ↗ |
| 2022-04-11 | JOHNSON WESLEY | Director | S-Sale | D | Common Stock | 6,201 | 23.00 | 142.6K | 80,003 | — | ↗ |
| 2022-02-03 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 583 | 20.48 | 11.9K | 75,498 | — | ↗ |
| 2022-02-01 | ROSENZWEIG RICHARD C | Officer | F-InKind | D | Common Stock | 1,194 | 21.31 | 25.4K | 12,904 | — | ↗ |
| 2022-01-12 | Trowbridge Stephen A | Officer | P-Purchase | A | Common Stock | 1,000 | 22.64 | 22.6K | 76,081 | — | ↗ |
| 2022-01-11 | Clemmer James C | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 22.84 | 228.4K | 390,764 | — | ↗ |
| 2021-10-31 | Centea Scott | Officer | F-InKind | D | Common Stock | 953 | 29.37 | 28.0K | 45,291 | — | ↗ |
| 2021-10-20 | Helsel Dave | Officer | S-Sale | D | Common Stock | 3,494 | 27.97 | 97.7K | 26,387 | — | ↗ |
| 2021-10-15 | Centea Scott | Officer | M-Exempt | D | Non-Qualified Stock Option (right to buy) | 12,000 | 16.77 | 201.2K | 0 | — | ↗ |
| 2021-10-05 | Campbell Chad Thomas | Officer | M-Exempt | D | Non-Qualified Stock Option (right to buy) | 10,748 | 16.59 | 178.3K | 0 | — | ↗ |
| 2021-09-22 | Nighan Warren JR | Officer | — | D | Non-Qualified Stock Option (right to buy) | 10,256 | 26.49 | 271.7K | 0 | — | ↗ |
| 2021-08-12 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 4,173 | 27.29 | 113.9K | 75,081 | — | ↗ |
| 2021-08-12 | Helsel Dave | Officer | M-Exempt | D | Performance Right | 6,945 | 0.00 | — | 0 | — | ↗ |
| 2021-08-12 | Clemmer James C | Director / Officer | M-Exempt | D | Performance Right | 34,938 | 0.00 | — | 0 | — | ↗ |
| 2021-08-12 | Campbell Chad Thomas | Officer | M-Exempt | D | Performance Right | 7,079 | 0.00 | — | 0 | — | ↗ |
| 2021-07-28 | Meteny Dennis S | Director | M-Exempt | A | Common Stock | 5,726 | 14.64 | 83.8K | 117,865 | — | ↗ |
| 2021-07-28 | JOHNSON WESLEY | Director | M-Exempt | A | Common Stock | 5,726 | 14.64 | 83.8K | 89,375 | — | ↗ |
| 2021-07-26 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 353 | 26.10 | 9.2K | 68,308 | — | ↗ |
| 2021-07-26 | Clemmer James C | Director / Officer | F-InKind | D | Common Stock | 2,105 | 26.10 | 54.9K | 359,167 | — | ↗ |
| 2021-07-26 | Centea Scott | Officer | F-InKind | D | Common Stock | 419 | 26.10 | 10.9K | 46,244 | — | ↗ |
| 2021-07-26 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 318 | 26.10 | 8.3K | 26,661 | — | ↗ |
| 2021-07-21 | Trowbridge Stephen A | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 20,128 | 10.27 | 206.7K | 20,128 | — | ↗ |
| 2021-07-21 | Tarnoff Michael E | Director | A-Award | A | Common Stock | 5,738 | 0.00 | — | 21,061 | — | ↗ |
| 2021-07-21 | ROSENZWEIG RICHARD C | Officer | A-Award | A | Common Stock | 3,098 | 0.00 | — | 14,098 | — | ↗ |
| 2021-07-21 | REED JAN STERN | Director | A-Award | A | Common Stock | 5,738 | 0.00 | — | 42,717 | — | ↗ |
| 2021-07-21 | Piccinini Laura | Officer | — | D | Non-Qualified Stock Option (right to buy) | 50,000 | 26.49 | 1.32M | 0 | — | ↗ |
| 2021-07-21 | Meteny Dennis S | Director | A-Award | A | Common Stock | 5,738 | 0.00 | — | 112,139 | — | ↗ |
| 2021-07-21 | Licitra Karen A | Director | A-Award | A | Common Stock | 5,738 | 0.00 | — | 28,118 | — | ↗ |
| 2021-07-21 | JOHNSON WESLEY | Director | A-Award | A | Common Stock | 5,738 | 0.00 | — | 83,649 | — | ↗ |
| 2021-07-21 | Helsel Dave | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 11,026 | 10.27 | 113.2K | 11,026 | — | ↗ |
| 2021-07-21 | DONNELLY HOWARD W | Director | A-Award | A | Common Stock | 5,738 | 0.00 | — | 98,712 | — | ↗ |
| 2021-07-21 | Clemmer James C | Director / Officer | A-Award | A | Common Stock | 26,189 | 0.00 | — | 361,272 | — | ↗ |
| 2021-07-21 | Centea Scott | Officer | A-Award | A | Common Stock | 2,842 | 0.00 | — | 46,663 | — | ↗ |
| 2021-07-21 | Campbell Chad Thomas | Officer | A-Award | A | Performance Right | 8,777 | 0.00 | — | 8,777 | — | ↗ |
| 2021-07-21 | Auen Eileen O'Shea | Director | A-Award | A | Common Stock | 5,738 | 0.00 | — | 42,401 | — | ↗ |
| 2021-07-18 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 400 | 24.76 | 9.9K | 61,253 | — | ↗ |
| 2021-07-18 | Helsel Dave | Officer | F-InKind | D | Common Stock | 417 | 24.76 | 10.3K | 17,764 | — | ↗ |
| 2021-07-18 | Clemmer James C | Director / Officer | F-InKind | D | Common Stock | 1,483 | 24.76 | 36.7K | 335,083 | — | ↗ |
| 2021-07-18 | Centea Scott | Officer | F-InKind | D | Common Stock | 344 | 24.76 | 8.5K | 43,821 | — | ↗ |
| 2021-07-18 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 300 | 24.76 | 7.4K | 22,591 | — | ↗ |
| 2021-07-17 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 354 | 24.76 | 8.8K | 61,653 | — | ↗ |
| 2021-07-17 | Helsel Dave | Officer | F-InKind | D | Common Stock | 294 | 24.76 | 7.3K | 18,181 | — | ↗ |
| 2021-07-17 | Clemmer James C | Director / Officer | F-InKind | D | Common Stock | 2,131 | 24.76 | 52.8K | 336,566 | — | ↗ |
| 2021-07-17 | Centea Scott | Officer | F-InKind | D | Common Stock | 339 | 24.76 | 8.4K | 44,165 | — | ↗ |
| 2021-07-17 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 262 | 24.76 | 6.5K | 22,891 | — | ↗ |
| 2021-07-14 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 1,284 | 26.43 | 33.9K | 62,007 | — | ↗ |
| 2021-07-14 | Helsel Dave | Officer | F-InKind | D | Common Stock | 640 | 26.43 | 16.9K | 18,475 | — | ↗ |
| 2021-07-14 | Clemmer James C | Director / Officer | F-InKind | D | Common Stock | 4,622 | 26.43 | 122.2K | 338,697 | — | ↗ |
| 2021-07-14 | Centea Scott | Officer | F-InKind | D | Common Stock | 500 | 26.43 | 13.2K | 44,504 | — | ↗ |
| 2021-07-14 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 571 | 26.43 | 15.1K | 23,153 | — | ↗ |
| 2021-04-15 | Trowbridge Stephen A | Officer | M-Exempt | A | Common Stock | 13,625 | 14.07 | 191.7K | 73,371 | — | ↗ |
| 2021-04-14 | Helsel Dave | Officer | S-Sale | D | Common Stock | 3,500 | 23.93 | 83.8K | 19,115 | — | ↗ |
| 2021-04-01 | DONNELLY HOWARD W | Director | M-Exempt | D | Non-Qualified Stock Option (right to buy) | 5,726 | 14.64 | 83.8K | 0 | — | ↗ |
| 2021-02-03 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 527 | 19.24 | 10.1K | 59,746 | — | ↗ |
| 2021-02-01 | ROSENZWEIG RICHARD C | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 62,000 | 18.92 | 1.17M | 62,000 | — | ↗ |
| 2021-01-20 | JOHNSON WESLEY | Director | S-Sale | D | Common Stock | 6,500 | 18.53 | 120.4K | 77,911 | — | ↗ |
| 2020-12-18 | Helsel Dave | Officer | F-InKind | D | Common Stock | 733 | 14.29 | 10.5K | 22,615 | — | ↗ |
| 2020-10-31 | Centea Scott | Officer | F-InKind | D | Common Stock | 849 | 10.62 | 9.0K | 45,004 | — | ↗ |
| 2020-09-03 | Centea Scott | Officer | — | D | Non-Qualified Stock Option (right to buy) | 17,640 | 9.92 | 175.0K | 0 | — | ↗ |
| 2020-08-11 | Trowbridge Stephen A | Officer | P-Purchase | A | Common Stock | 1,013 | 9.38 | 9.5K | 60,273 | — | ↗ |
| 2020-07-31 | Clemmer James C | Director / Officer | P-Purchase | A | Common Stock | 40,000 | 8.26 | 330.4K | 343,319 | — | ↗ |
| 2020-07-27 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 292 | 8.80 | 2.6K | 59,260 | — | ↗ |
| 2020-07-27 | Clemmer James C | Director / Officer | F-InKind | D | Common Stock | 1,799 | 8.80 | 15.8K | 303,319 | — | ↗ |
| 2020-07-27 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 259 | 8.80 | 2.3K | 23,724 | — | ↗ |
| 2020-07-26 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 314 | 8.80 | 2.8K | 59,552 | — | ↗ |
| 2020-07-26 | Clemmer James C | Director / Officer | F-InKind | D | Common Stock | 1,876 | 8.80 | 16.5K | 305,118 | — | ↗ |
| 2020-07-26 | Campbell Chad Thomas | Officer | F-InKind | D | Common Stock | 283 | 8.80 | 2.5K | 23,983 | — | ↗ |
| 2020-07-18 | Trowbridge Stephen A | Officer | F-InKind | D | Common Stock | 248 | 9.21 | 2.3K | 60,018 | — | ↗ |
Executive team
Executive compensation
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | James C. Clemmer President, CEO | 803.0K | — | 2.63M | 808.2K | 1.22M | 38.6K | 5.49M | 62.56% | ↗ |
| 2 | 2025 | Stephen A. Trowbridge EVP, CFO | 455.8K | — | 934.1K | 287.5K | 449.7K | 34.7K | 2.16M | 56.51% | ↗ |
| 3 | 2025 | Laura Piccinini SVP & GM, Cardiovascular and International | 410.1K | — | 414.8K | 112.3K | 371.8K | 60.5K | 1.37M | 38.49% | ↗ |
| 4 | 2025 | Lawrence T. Weiss SVP & Chief Legal Officer | 206.7K | — | 376.3K | 386.7K | 193.5K | 6.9K | 1.17M | 65.20% | ↗ |
| 5 | 2025 | Warren Nighan SVP & GM, Global Supply Chain, Quality and Regulatory Affairs | 401.3K | — | 337.2K | 88.4K | 303.4K | 34.9K | 1.17M | 36.53% | ↗ |
| 6 | 2024 | James C. Clemmer President, CEO | 783.0K | — | 2.58M | 820.0K | 783.0K | 40.8K | 5.01M | 67.90% | ↗ |
| 7 | 2024 | Stephen A. Trowbridge EVP, CFO | 441.3K | — | 802.8K | 255.2K | 286.9K | 36.1K | 1.82M | 58.06% | ↗ |
| 8 | 2024 | Laura Piccinini SVP & GM, Endovascular Therapies and International | 401.3K | — | 396.4K | 126.0K | 240.8K | 64.9K | 1.23M | 42.50% | ↗ |
| 9 | 2024 | Laura Piccinini SVP & GM, Cardiovascular and International | 401.3K | — | 396.4K | 126.0K | 240.8K | 64.9K | 1.23M | 42.50% | ↗ |
| 10 | 2024 | Chad T. Campbell SVP & GM, Global Oncology and Vascular Access | 353.2K | — | 318.5K | 101.3K | 211.9K | 27.7K | 1.01M | 41.46% | ↗ |
| 11 | 2024 | Warren Nighan SVP & GM, Global Supply Chain, Quality and Regulatory Affairs | 392.7K | — | 280.5K | 89.2K | 196.4K | 36.3K | 995.1K | 37.15% | ↗ |
| 12 | 2023 | James C. Clemmer President, CEO | 756.2K | — | 2.28M | 719.0K | 190.0K | 36.8K | 3.98M | 75.33% | ↗ |
| 13 | 2023 | Stephen A. Trowbridge EVP, CFO | 425.3K | — | 548.9K | 172.9K | 69.6K | 33.1K | 1.25M | 57.75% | ↗ |
| 14 | 2023 | Laura Piccinini SVP & GM, International | 334.4K | — | 303.5K | 95.6K | 50.4K | 59.5K | 843.4K | 47.32% | ↗ |
| 15 | 2023 | Laura Piccinini SVP & GM, Endovascular Therapies and International | 334.4K | — | 303.5K | 95.6K | 50.4K | 59.5K | 843.4K | 47.32% | ↗ |
| 16 | 2023 | Laura Piccinini SVP & GM, Cardiovascular and International | 334.4K | — | 303.5K | 95.6K | 50.4K | 59.5K | 843.4K | 47.32% | ↗ |
| 17 | 2023 | David D. Helsel SVP, Global Operations and R&D | 371.3K | — | 254.5K | 80.2K | 46.7K | 33.0K | 785.6K | 42.60% | ↗ |
| 18 | 2023 | Chad T. Campbell SVP & GM, Global Oncology and Vascular Access | 339.7K | — | 274.9K | 86.6K | 51.4K | 25.3K | 778.0K | 46.47% | ↗ |
| 19 | 2023 | Chad T. Campbell SVP & GM, Vascular Access and Oncology | 339.7K | — | 274.9K | 86.6K | 51.4K | 25.3K | 778.0K | 46.47% | ↗ |
| 20 | 2022 | James C. Clemmer President, CEO | 736.2K | — | 3.16M | 991.3K | 740.0K | 35.9K | 5.66M | 73.28% | ↗ |
| 21 | 2022 | Laura Piccinini SVP & GM, Endovascular Therapies and International | 355.7K | — | 483.9K | 510.6K | 177.8K | 101.0K | 1.63M | 61.05% | ↗ |
| 22 | 2022 | Laura Piccinini SVP & GM, International | 355.7K | — | 483.9K | 510.6K | 177.8K | 101.0K | 1.63M | 61.05% | ↗ |
| 23 | 2022 | Stephen A. Trowbridge EVP, CFO | 409.7K | — | 624.9K | 196.3K | 267.8K | 32.1K | 1.53M | 53.64% | ↗ |
| 24 | 2022 | Chad T. Campbell SVP & GM, Vascular Access and Oncology | 324.1K | — | 370.2K | 116.3K | 195.9K | 24.1K | 1.03M | 47.20% | ↗ |
| 25 | 2022 | Chad T. Campbell SVP & GM, Global Oncology and Vascular Access | 324.1K | — | 370.2K | 116.3K | 195.9K | 24.1K | 1.03M | 47.20% | ↗ |
| 26 | 2022 | David D. Helsel SVP, Global Operations and R&D | 360.5K | — | 342.3K | 107.5K | 181.3K | 32.0K | 1.02M | 43.94% | ↗ |
| 27 | 2021 | James C. Clemmer President, CEO | 720.0K | — | 1.60M | 539.2K | 1.15M | 36.5K | 4.05M | 52.83% | ↗ |
| 28 | 2021 | Stephen A. Trowbridge EVP, CFO | 400.0K | — | 443.9K | 149.8K | 384.0K | 29.0K | 1.41M | 42.21% | ↗ |
| 29 | 2021 | David D. Helsel SVP, Global Operations and R&D | 352.0K | — | 221.4K | 74.7K | 281.6K | 30.7K | 960.4K | 30.83% | ↗ |
| 30 | 2021 | Warren G. Nighan SVP, Quality and Regulatory Affairs | 327.0K | — | 205.7K | 69.4K | 261.6K | 33.5K | 897.2K | 30.66% | ↗ |
| 31 | 2021 | Chad T. Campbell SVP & GM, Vascular Access | 314.0K | 2.9K | 197.5K | 66.6K | 251.2K | 21.6K | 853.9K | 30.93% | ↗ |
| 32 | 2021 | Chad T. Campbell SVP & GM, Vascular Access and Oncology | 314.0K | 2.9K | 197.5K | 66.6K | 251.2K | 21.6K | 853.9K | 30.93% | ↗ |
| 33 | 2020 | James C. Clemmer President, CEO | 716.2K | — | 1.25M | 540.6K | 576.0K | 38.2K | 3.12M | 57.31% | ↗ |
| 34 | 2020 | Michael C. Greiner Former EVP, CFO | 270.8K | — | 380.4K | 165.0K | — | 462.7K | 1.28M | 42.65% | ↗ |
| 35 | 2020 | Stephen A. Trowbridge EVP, CFO | 401.4K | — | 281.4K | 164.7K | 194.0K | 34.1K | 1.08M | 41.47% | ↗ |
| 36 | 2020 | Scott Centea SVP and GM, Peripheral Vascular | 261.7K | — | 239.0K | 230.7K | 84.9K | 25.0K | 841.4K | 55.83% | ↗ |
| 37 | 2020 | David D. Helsel SVP, Global Operations and R&D | 349.8K | — | 172.5K | 74.8K | 140.8K | 31.5K | 769.4K | 32.14% | ↗ |
| 38 | 2020 | Brent J. Boucher Former SVP, Oncology | 324.5K | — | 160.2K | 69.5K | 130.8K | 31.5K | 716.5K | 32.05% | ↗ |
| 39 | 2019 | James C. Clemmer President, CEO | 686.6K | — | 1.20M | 365.2K | 714.0K | 37.5K | 3.00M | 52.09% | ↗ |
| 40 | 2019 | Michael C. Greiner EVP, CFO | 419.0K | — | 479.3K | 146.1K | 279.8K | 31.2K | 1.36M | 46.14% | ↗ |
| 41 | 2019 | Michael C. Greiner Former EVP, CFO | 419.0K | — | 479.3K | 146.1K | 279.8K | 31.2K | 1.36M | 46.14% | ↗ |
| 42 | 2019 | David D. Helsel SVP, Global Operations and R&D | 333.9K | — | 337.2K | 102.8K | 156.5K | 27.8K | 958.3K | 45.92% | ↗ |
| 43 | 2019 | Robert A. Simpson SVP and GM, Peripheral Vascular | 337.2K | — | 325.7K | 99.3K | 156.1K | 32.7K | 950.9K | 44.69% | ↗ |
| 44 | 2019 | Stephen A. Trowbridge EVP, CFO | 333.9K | — | 323.7K | 98.7K | 154.7K | 30.5K | 941.4K | 44.86% | ↗ |
| 45 | 2019 | Stephen A. Trowbridge SVP and General Counsel | 333.9K | — | 323.7K | 98.7K | 154.7K | 30.5K | 941.4K | 44.86% | ↗ |
| 46 | 2018 | James C. Clemmer President, CEO | 643.3K | — | 1.42M | 366.6K | 273.0K | 41.2K | 2.74M | 65.09% | ↗ |
| 47 | 2018 | Michael C. Greiner EVP, CFO | 399.2K | — | 397.7K | 102.8K | 111.9K | 31.4K | 1.04M | 47.98% | ↗ |
| 48 | 2018 | David D. Helsel SVP, Global Operations and R&D | 133.5K | — | 410.3K | 252.1K | 24.8K | 6.1K | 826.8K | 80.11% | ↗ |
| 49 | 2018 | Robert A. Simpson SVP and GM, Peripheral Vascular | 330.0K | — | 240.1K | 62.0K | 62.4K | 124.2K | 818.7K | 36.90% | ↗ |
| 50 | 2018 | Stephen A. Trowbridge EVP, CFO | 323.3K | — | 237.9K | 61.5K | 61.8K | 34.2K | 718.6K | 41.66% | ↗ |
| 51 | 2018 | Stephen A. Trowbridge SVP and General Counsel | 323.3K | — | 237.9K | 61.5K | 61.8K | 34.2K | 718.6K | 41.66% | ↗ |
| 52 | 2017 | James C. Clemmer President, Chief Executive Officer | 625.0K | — | 351.6K | 351.7K | 493.8K | 19.0K | 1.84M | 38.20% | ↗ |
| 53 | 2017 | James C. Clemmer President, CEO | 625.0K | — | 351.6K | 351.7K | 490.6K | 19.0K | 1.84M | 38.27% | ↗ |
| 54 | 2017 | Michael C. Greiner EVP, CFO | 280.3K | 100.0K | 612.9K | 453.0K | 177.6K | 47.3K | 1.67M | 63.78% | ↗ |
| 55 | 2017 | Michael C. Greiner Executive Vice President, Chief Financial Officer | 280.3K | 100.0K | 612.9K | 453.0K | 177.6K | 47.3K | 1.67M | 63.78% | ↗ |
| 56 | 2017 | Robert A. Simpson Senior Vice President Peripheral Vascular | 100.3K | — | 839.3K | 243.0K | 39.6K | 5.8K | 1.23M | 88.13% | ↗ |
| 57 | 2017 | Robert A. Simpson SVP and GM, Peripheral Vascular | 100.3K | — | 839.3K | 243.0K | 39.6K | 5.8K | 1.23M | 88.13% | ↗ |
| 58 | 2017 | Chad T. Campbell Senior Vice President Global Vascular Access | 270.0K | — | 354.5K | 404.0K | 85.6K | 49.7K | 1.16M | 65.18% | ↗ |
| 59 | 2017 | Stephen A. Trowbridge Senior Vice President and General Counsel | 311.7K | — | 213.1K | 57.2K | 113.1K | 23.1K | 718.1K | 37.64% | ↗ |
| 60 | 2017 | Stephen A. Trowbridge SVP and General Counsel | 311.7K | — | 213.1K | 57.2K | 113.1K | 23.1K | 718.1K | 37.64% | ↗ |
| 61 | 2016 | James C. Clemmer President, Chief Executive Officer | 84.1K | — | 4.85M | 706.7K | — | 2.4K | 5.64M | 98.47% | ↗ |
| 62 | 2016 | James C. Clemmer President, CEO | 84.1K | — | 4.85M | 706.7K | — | 2.4K | 5.64M | 98.47% | ↗ |
| 63 | 2016 | Joseph M. DeVivo Former President, Chief Executive Officer | 565.3K | 6.4K | 1.24M | 445.5K | — | 658.6K | 2.92M | 57.83% | ↗ |
| 64 | 2016 | John Soto Former Executive Vice President and Chief Commercial Officer | 318.2K | — | 240.2K | 86.2K | — | 379.4K | 1.02M | 31.87% | ↗ |
| 65 | 2016 | Mark A. Stephens Sr. Vice President—Administration | 305.6K | — | 192.3K | 69.0K | 68.1K | 30.5K | 665.4K | 39.26% | ↗ |
| 66 | 2016 | Stephen A. Trowbridge Sr. Vice President and General Counsel | 302.3K | — | 190.4K | 68.3K | 61.8K | 30.0K | 652.8K | 39.64% | ↗ |
| 67 | 2016 | Stephen A. Trowbridge SVP and General Counsel | 302.3K | — | 190.4K | 68.3K | 61.8K | 30.0K | 652.8K | 39.64% | ↗ |
| 68 | 2016 | Stephen A. Trowbridge Senior Vice President and General Counsel | 302.3K | — | 190.4K | 68.3K | 61.8K | 30.0K | 652.8K | 39.64% | ↗ |
| 69 | 2016 | Mark T. Frost Former Executive Vice President— Chief Financial Officer | 183.7K | — | 264.2K | 94.8K | — | 13.6K | 556.3K | 64.52% | ↗ |
| 70 | 2016 | Michael Trimarchi Vice President—Interim Chief Financial Officer | 200.4K | 80.0K | 79.8K | — | — | 26.7K | 386.9K | 20.61% | ↗ |
| 71 | 2015 | Joseph M. DeVivo Former President, Chief Executive Officer | 638.7K | — | 1.25M | 366.1K | 420.7K | 24.0K | 2.70M | 59.88% | ↗ |
| 72 | 2015 | Joseph M. DeVivo President, Chief Executive Officer | 638.7K | — | 1.25M | 366.1K | 420.7K | 24.0K | 2.70M | 59.88% | ↗ |
| 73 | 2015 | Stephen A. Trowbridge Senior Vice President and General Counsel | 293.8K | — | 448.3K | 56.1K | 96.4K | 29.1K | 923.7K | 54.61% | ↗ |
| 74 | 2015 | Stephen A. Trowbridge Sr. Vice President and General Counsel | 293.8K | — | 448.3K | 56.1K | 96.4K | 29.1K | 923.7K | 54.61% | ↗ |
| 75 | 2015 | Mark T. Frost Executive Vice President—Chief Financial Officer | 360.5K | — | 266.1K | 77.9K | 119.9K | 28.8K | 853.3K | 40.32% | ↗ |
| 76 | 2015 | Mark T. Frost Former Executive Vice President— Chief Financial Officer | 360.5K | — | 266.1K | 77.9K | 119.9K | 28.8K | 853.3K | 40.32% | ↗ |
| 77 | 2015 | John Soto Former Executive Vice President and Chief Commercial Officer | 327.0K | — | 242.0K | 70.8K | 109.3K | 14.4K | 763.6K | 40.97% | ↗ |
| 78 | 2015 | John Soto Executive Vice President and Chief Commercial Officer | 327.0K | — | 242.0K | 70.8K | 109.3K | 14.4K | 763.6K | 40.97% | ↗ |
| 79 | 2015 | Mark A. Stephens Sr. Vice President—Administration | 295.9K | — | 193.7K | 56.7K | 97.3K | 31.6K | 675.2K | 37.08% | ↗ |
| 80 | 2014 | Joseph M. DeVivo President, Chief Executive Officer | 599.5K | 250.0K | 2.47M | 219.2K | 70.7K | 27.9K | 3.64M | 73.96% | ↗ |
| 81 | 2014 | Joseph M. DeVivo Former President, Chief Executive Officer | 599.5K | 250.0K | 2.47M | 219.2K | 70.7K | 27.9K | 3.64M | 73.96% | ↗ |
| 82 | 2014 | Mark T. Frost Former Executive Vice President— Chief Financial Officer | 353.4K | — | 345.9K | 89.9K | 24.0K | 20.7K | 833.8K | 52.26% | ↗ |
| 83 | 2014 | Mark T. Frost Executive Vice President—Chief Financial Officer | 353.4K | — | 345.9K | 89.9K | 24.0K | 20.7K | 833.8K | 52.26% | ↗ |
| 84 | 2014 | Mark A. Stephens Sr. Vice President—Administration | 285.8K | — | 246.7K | 64.1K | 22.5K | 42.8K | 656.7K | 47.33% | ↗ |
| 85 | 2014 | Stephen A. Trowbridge Sr. Vice President and General Counsel | 280.6K | — | 246.7K | 64.1K | 28.9K | 32.9K | 650.1K | 47.81% | ↗ |
| 86 | 2014 | John Soto Executive Vice President and Chief Commercial Officer | 295.9K | — | 239.0K | 62.1K | 26.8K | 11.6K | 635.4K | 47.38% | ↗ |
| 87 | 2014 | John Soto Former Executive Vice President and Chief Commercial Officer | 295.9K | — | 239.0K | 62.1K | 26.8K | 11.6K | 635.4K | 47.38% | ↗ |
| 88 | 2014 | George W. Bourne IV Sr. Vice President and Chief Technology and Operations Officer | 335.2K | — | 72.2K | 73.0K | 23.9K | 11.5K | 515.8K | 28.14% | ↗ |
| 89 | 2013 | Joseph M. DeVivo President, Chief Executive Officer | 568.6K | — | 236.5K | 146.0K | — | 65.0K | 1.02M | 37.64% | ↗ |
| 90 | 2013 | Mark T. Frost Executive Vice President—Chief Financial Officer | 167.2K | — | 247.8K | 424.0K | — | 6.9K | 845.9K | 79.42% | ↗ |
| 91 | 2013 | John Soto Executive Vice President and Chief Commercial Officer | 192.1K | — | 103.7K | 202.0K | — | 81.2K | 579.0K | 52.80% | ↗ |
| 92 | 2013 | Stephen J. McGill Sr. Vice President and General Manager— International | 299.7K | — | 159.5K | 62.6K | — | 50.8K | 572.5K | 38.78% | ↗ |
| 93 | 2013 | D. Joseph Gersuk Executive Vice President—Chief Financial Officer | 230.3K | — | 127.6K | 52.1K | — | 134.7K | 544.8K | 32.99% | ↗ |
| 94 | 2013 | Mark A. Stephens Sr. Vice President—Administration | 96.2K | 15.0K | 123.9K | 212.0K | — | 65.1K | 512.1K | 65.59% | ↗ |
| 95 | 2013 | Richard A. Stark Sr. Vice President—Global Franchise— Oncology/Surgery | 276.8K | — | 106.3K | 41.7K | — | 29.8K | 454.6K | 32.56% | ↗ |
| 96 | 2013 | Alan Panzer Sr. Vice President and General Manager— US Sales | 307.4K | — | 79.7K | 41.7K | — | 21.9K | 450.7K | 26.95% | ↗ |
| 97 | 2013 | George W. Bourne IV Sr. Vice President and Chief Technology and Operations Officer | 301.5K | — | 21.7K | 18.6K | — | 2.2K | 344.0K | 11.72% | ↗ |
| 98 | 2013 | Stephen A. Trowbridge Sr. Vice President and General Counsel | 203.4K | — | 106.3K | — | — | 30.2K | 339.9K | 31.28% | ↗ |
| 99 | 2012 | Joseph M. DeVivo President, Chief Executive Officer | 401.3K | — | 348.0K | 2.29M | 208.1K | 288.7K | 3.53M | 74.57% | ↗ |
| 100 | 2012 | Alan Panzer Sr. Vice President and General Manager— US Sales | 213.5K | — | 310.0K | 623.1K | 16.5K | 101.2K | 1.26M | 73.80% | ↗ |
| 101 | 2012 | Jan Keltjens President, Chief Executive Officer | 29.9K | — | — | — | — | 952.5K | 982.4K | 0.00% | ↗ |
| 102 | 2012 | D. Joseph Gersuk Executive Vice President—Chief Financial Officer | 329.3K | — | 121.8K | 68.9K | 38.3K | 31.8K | 590.1K | 32.31% | ↗ |
| 103 | 2012 | Stephen J. McGill Sr. Vice President and General Manager— International | 296.1K | — | 81.2K | 57.9K | 31.0K | 30.4K | 496.6K | 28.00% | ↗ |
| 104 | 2012 | R. Scott Etlinger Sr. Vice President—Global Operations | 293.5K | — | 81.2K | 57.9K | 20.5K | 13.3K | 466.3K | 29.81% | ↗ |
| 105 | 2012 | Richard A. Stark Sr. Vice President—Global Franchise— Oncology/Surgery | 249.6K | — | 115.0K | — | 13.3K | 14.9K | 392.8K | 29.28% | ↗ |
| 106 | 2012 | George W. Bourne IV Sr. Vice President and Chief Technology and Operations Officer | 5.6K | — | 124.4K | 247.5K | — | — | 377.5K | 98.52% | ↗ |
| 107 | 2012 | Scott J. Solano President, Chief Executive Officer | 128.4K | — | 143.6K | 57.9K | — | 44.1K | 374.0K | 53.88% | ↗ |
| 108 | 2011 | Jan Keltjens President, Chief Executive Officer | 425.0K | — | 315.0K | 486.7K | — | 33.7K | 1.26M | 63.61% | ↗ |
| 109 | 2011 | Stephen J. McGill Sr. Vice President and General Manager— International | 277.6K | — | 217.5K | 329.4K | 20.5K | 30.3K | 875.3K | 62.49% | ↗ |
| 110 | 2011 | D. Joseph Gersuk Executive Vice President—Chief Financial Officer | 308.2K | — | 236.3K | 173.8K | 27.8K | 30.2K | 776.3K | 52.83% | ↗ |
| 111 | 2011 | Shawn P. McCarthy Sr. Vice President—General Manager | 290.3K | — | 126.0K | 139.1K | — | 201.6K | 756.9K | 35.02% | ↗ |
| 112 | 2011 | Scott J. Solano President, Chief Executive Officer | 195.4K | — | — | 469.8K | 17.1K | 6.0K | 688.4K | 68.26% | ↗ |
| 113 | 2011 | Scott J. Solano Sr. Vice President— CTO | 195.4K | — | — | 469.8K | 17.1K | 6.0K | 688.4K | 68.26% | ↗ |
| 114 | 2011 | R. Scott Etlinger Sr. Vice President—Global Operations | 201.0K | — | — | 313.2K | 13.2K | 109.8K | 637.2K | 49.16% | ↗ |
| 115 | 2011 | Richard A. Stark Sr. Vice President—Global Franchise— Oncology/Surgery | 221.2K | — | 128.0K | — | 43.1K | 13.1K | 405.3K | 31.57% | ↗ |
| 116 | 2010 | D. Joseph Gersuk Executive Vice President—Chief Financial Officer | 302.4K | — | 159.5K | 76.3K | 162.2K | 40.9K | 741.2K | 31.81% | ↗ |
| 117 | 2010 | D. Joseph Gersuk Executive Vice President —Chief Financial Officer | 302.4K | — | 159.5K | 76.3K | 162.2K | 40.9K | 741.2K | 31.81% | ↗ |
| 118 | 2010 | Shawn P. McCarthy Sr. Vice President—General Manager | 198.8K | — | 185.1K | 242.0K | 79.5K | 18.5K | 723.9K | 59.00% | ↗ |
| 119 | 2010 | Shawn P. McCarthy Sr. Vice President— General Manager | 198.8K | — | 185.1K | 242.0K | 79.5K | 18.5K | 723.9K | 59.00% | ↗ |
| 120 | 2010 | Jan Keltjens President, Chief Executive Officer | 425.0K | — | — | — | 238.4K | 34.8K | 698.1K | 0.00% | ↗ |
| 121 | 2010 | William M. Appling Sr. Vice President— Advanced Research | 204.0K | — | 119.6K | 50.8K | 71.8K | 35.1K | 481.4K | 35.41% | ↗ |
| 122 | 2010 | Harold C. Mapes Sr. Vice President— Operations | 221.8K | — | 66.5K | 31.8K | 70.0K | 28.1K | 418.1K | 23.50% | ↗ |
| 123 | 2010 | Stephen J. McGill Sr. Vice President and General Manager— International | 156.5K | — | — | — | 43.6K | 24.8K | 224.9K | 0.00% | ↗ |
| 124 | 2009 | Jan Keltjens President, Chief Executive Officer | 106.3K | — | 1.00M | 1.12M | 74.4K | 4.4K | 2.31M | 91.97% | ↗ |
| 125 | 2009 | D. Joseph Gersuk Executive Vice President —Chief Financial Officer | 295.0K | — | 124.0K | 101.5K | 108.6K | 42.3K | 671.4K | 33.59% | ↗ |
| 126 | 2009 | D. Joseph Gersuk Executive Vice President—Chief Financial Officer | 295.0K | — | 124.0K | 101.5K | 108.6K | 42.3K | 671.4K | 33.59% | ↗ |
| 127 | 2009 | Harold C. Mapes Sr. Vice President— Operations | 218.5K | — | 99.2K | 81.2K | 48.4K | 37.8K | 485.1K | 37.19% | ↗ |
| 128 | 2009 | William M. Appling Sr. Vice President— Advanced Research | 200.0K | — | 99.2K | 81.2K | 45.7K | 37.2K | 463.3K | 38.94% | ↗ |
| 129 | 2008 | Eamonn P. Hobbs President, Chief Executive Officer | 328.7K | 130.0K | 68.1K | 436.6K | — | 12.7K | 976.1K | 51.70% | ↗ |
| 130 | 2008 | D. Joseph Gersuk Executive Vice President—Chief Financial Officer | 259.3K | 92.2K | 17.9K | 99.2K | — | 649.00 | 567.8K | 20.62% | ↗ |
| 131 | 2008 | D. Joseph Gersuk Executive Vice President —Chief Financial Officer | 259.3K | — | — | 75.1K | 92.2K | 32.5K | 459.1K | 16.35% | ↗ |
| 132 | 2008 | William M. Appling Sr. Vice President— Advanced Research | 183.6K | — | — | 181.0K | 56.6K | 32.9K | 454.2K | 39.86% | ↗ |
| 133 | 2008 | William M. Appling Sr. Vice President— R&D | 183.6K | 56.6K | 33.0K | 113.9K | — | 12.0K | 399.2K | 36.80% | ↗ |
| 134 | 2008 | Robert M. Rossell Vice President— Corporate Accounts | 192.7K | 51.0K | 33.0K | 104.7K | — | 12.2K | 393.6K | 34.99% | ↗ |
| 135 | 2008 | Harold C. Mapes Vice President— Operations | 190.4K | 49.8K | 33.0K | 108.3K | — | 12.0K | 393.5K | 35.92% | ↗ |
| 136 | 2008 | Harold C. Mapes Sr. Vice President— Operations | 190.4K | — | — | 121.0K | 49.8K | 27.6K | 388.7K | 31.12% | ↗ |
| 137 | 2008 | Robert D. Mitchell Executive Vice President— Chief Operating Officer | 232.2K | 29.5K | — | 118.2K | — | 3.7K | 383.6K | 30.80% | ↗ |
| 138 | 2008 | John S. Soto Sr. Vice President— Global Sales | 200.0K | 24.0K | — | 35.2K | — | — | 259.3K | 13.57% | ↗ |
| 139 | 2007 | Eamonn P. Hobbs President, Chief Executive Officer | 313.0K | 88.0K | 71.3K | 305.1K | — | 37.1K | 814.5K | 46.21% | ↗ |
| 140 | 2007 | John S. Soto Sr. Vice President— Global Sales | 62.2K | 18.1K | — | — | — | 272.0K | 352.2K | 0.00% | ↗ |
| 141 | 2007 | John Soto Vice President—Global Sales | 62.2K | 18.1K | — | — | — | 272.0K | 352.2K | 0.00% | ↗ |
| 142 | 2007 | Robert M. Rossell Vice President— Corporate Accounts | 185.4K | 27.1K | 35.6K | 73.8K | — | 28.9K | 350.7K | 31.18% | ↗ |
| 143 | 2007 | Robert Rossell Vice President—Corporate Accounts | 185.4K | 27.1K | 35.6K | 73.8K | — | 28.9K | 350.7K | 31.18% | ↗ |
| 144 | 2007 | Harold Mapes Vice President—Operations | 183.0K | 27.6K | 35.6K | 74.7K | — | 23.0K | 343.8K | 32.07% | ↗ |
| 145 | 2007 | Harold C. Mapes Vice President— Operations | 183.0K | 27.6K | 35.6K | 74.7K | — | 23.0K | 343.8K | 32.07% | ↗ |
| 146 | 2007 | William M. Appling Sr. Vice President— R&D | 176.6K | 29.0K | 35.6K | 71.8K | — | 9.5K | 322.5K | 33.30% | ↗ |
| 147 | 2007 | Joseph Gerardi Vice President—Special Projects | 164.9K | 27.8K | 35.6K | 58.9K | — | 26.9K | 314.1K | 30.08% | ↗ |
| 148 | 2007 | Robert D. Mitchell Executive Vice President— Chief Operating Officer | 148.5K | 20.6K | 33.9K | 48.8K | — | 50.0K | 301.8K | 27.41% | ↗ |
| 149 | 2007 | D. Joseph Gersuk Executive Vice President—Chief Financial Officer | 29.4K | 46.0K | 1.5K | 7.4K | — | 3.7K | 88.0K | 10.10% | ↗ |
| 150 | 2007 | Joseph Gersuk Executive Vice President—Chief Financial Officer | 29.4K | 46.0K | 1.5K | 7.4K | — | 3.7K | 88.0K | 10.10% | ↗ |
| 151 | 2006 | Eamonn P. Hobbs President, Chief Executive Officer | 289.0K | 104.6K | — | 45.0K | — | 12.5K | 451.2K | 9.97% | ↗ |
| 152 | 2006 | Paul J. Shea Vice President | 181.4K | 49.3K | — | 10.2K | — | 11.1K | 252.0K | 4.05% | ↗ |
| 153 | 2006 | Robert M. Rossell Vice President | 176.6K | 47.9K | — | 10.2K | — | 11.7K | 246.4K | 4.14% | ↗ |
| 154 | 2006 | Brian S. Kunst Vice President | 170.1K | 46.2K | — | 10.2K | — | 11.5K | 238.0K | 4.29% | ↗ |
| 155 | 2006 | William M. Appling Vice President | 168.1K | 45.6K | — | 10.2K | — | 11.4K | 235.4K | 4.33% | ↗ |
| 156 | 2005 | Eamonn P. Hobbs President, Chief Executive Officer | 267.0K | 140.2K | 310.5K | 35.5K | — | 10.8K | 764.0K | 45.29% | ↗ |
| 157 | 2005 | Paul J. Shea Vice President | 168.0K | 74.1K | 150.6K | 10.2K | — | 10.0K | 412.8K | 38.94% | ↗ |
| 158 | 2005 | Robert M. Rossell Vice President | 163.5K | 73.6K | 150.6K | 10.2K | — | 10.3K | 408.1K | 39.39% | ↗ |
| 159 | 2005 | Brian S. Kunst Vice President | 157.5K | 70.9K | 150.6K | 8.0K | — | 9.9K | 396.8K | 39.96% | ↗ |
| 160 | 2005 | William M. Appling Vice President | 155.6K | 69.6K | 150.6K | 10.2K | — | 10.2K | 396.2K | 40.58% | ↗ |
| 161 | 2004 | Eamonn P. Hobbs President, Chief Executive Officer | 254.4K | 126.9K | — | — | — | 10.6K | 391.9K | 0.00% | ↗ |
| 162 | 2004 | Robert M. Rossell Vice President | 156.0K | 65.3K | — | — | — | 11.1K | 232.4K | 0.00% | ↗ |
| 163 | 2004 | Paul J. Shea Vice President | 156.0K | 65.3K | — | — | — | 11.1K | 232.4K | 0.00% | ↗ |
| 164 | 2004 | William M. Appling Vice President | 148.5K | 63.5K | — | — | — | 10.5K | 222.5K | 0.00% | ↗ |
| 165 | 2004 | Brian S. Kunst Vice President | 143.0K | 59.8K | — | — | — | 10.0K | 212.9K | 0.00% | ↗ |
| 166 | 2003 | Eamonn P. Hobbs President, Chief Executive Officer | 240.0K | 96.6K | — | — | — | 8.5K | 345.1K | 0.00% | ↗ |
| 167 | 2003 | Paul J. Shea Vice President | 150.0K | 63.8K | — | — | — | 8.4K | 222.2K | 0.00% | ↗ |
| 168 | 2003 | Robert M. Rossell Vice President | 150.0K | 63.8K | — | — | — | 8.4K | 222.2K | 0.00% | ↗ |
| 169 | 2003 | William M. Appling Vice President | 135.0K | 57.9K | — | — | — | 8.5K | 201.5K | 0.00% | ↗ |
| 170 | 2003 | Brian S. Kunst Vice President | 130.0K | 55.6K | — | — | — | 8.5K | 194.1K | 0.00% | ↗ |
| 171 | 2002 | Eamonn P. Hobbs President, Chief Executive Officer | 218.8K | 114.9K | — | — | — | 22.8K | 356.5K | 0.00% | ↗ |
| 172 | 2002 | Paul J. Shea Vice President | 136.8K | 61.5K | — | — | — | 8.2K | 206.5K | 0.00% | ↗ |
| 173 | 2002 | Robert M. Rossell Vice President | 136.8K | 61.5K | — | — | — | 8.2K | 206.5K | 0.00% | ↗ |
| 174 | 2002 | William M. Appling Vice President | 125.0K | 56.3K | — | — | — | 7.8K | 189.1K | 0.00% | ↗ |
| 175 | 2002 | Brian S. Kunst Vice President | 119.8K | 53.9K | — | — | — | 7.5K | 181.3K | 0.00% | ↗ |
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James C. Clemmer | Chief Executive Officer, President & Director | 2M | male |
| Stephen A. Trowbridge | Executive Vice President & Chief Financial Officer | 940.2K | male |
| Laura Piccinini | Senior Vice President and GM of Cardiovascular & International | 842.3K | female |
| Warren G. Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain | 739.6K | male |
| Lawrence T. Weiss | Senior Vice President, Chief Legal Officer & Corporate Secretary | 696.6K | male |
| Chad T. Campbell | Senior Vice President and GM of Oncology & Interventional Devices | 592.8K | male |
| Benjamin H. Davis | Senior Vice President of Business Development & Strategy | — | male |
| Marna I. Bronfen-Moore | Senior Vice President of Human Resources | — | female |
| Saleem Cheeks | Vice President of Communications | — | male |
| Kim L. Seabury | Senior Vice President of Information Technology | — | female |
No Senate trading activity found for this company.
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-10-20 | 2025-10-27 | Debbie Wasserman Schultz | FL25 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-07-16 | 2025-07-28 | Debbie Wasserman Schultz | FL25 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-06-27 | 2025-07-28 | Debbie Wasserman Schultz | FL25 | — | Purchase | $1,001 - $15,000 | ↗ |
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ANGO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
